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La lesión hepática inducida por fármacos (DILI) es una de las principales causas de 
lesión hepática aguda, incluida la sobredosis de acetaminofén (APAP). El estrés del 
retículo endoplásmico (ER) es un mecanismo sin explorar, pero muy probablemente, 
desencadenante de la lesión hepática inducida por APAP. En condiciones de estrés, ER 
puede iniciar la respuesta de proteína desplegada. Sin embargo, los mecanismos del 
estrés ER y UPR siguen siendo poco conocidos. En este estudio, nuestro objetivo 
general fue develar la relevancia del brazo IRE1α-XBP1, el brazo más conservado de 
UPR, durante la insuficiencia hepática aguda inducida por APAP y proporcionar la base 
para la intervención terapéutica. 
Métodos 
Los HepaRG se desafiaron con diferentes concentraciones de APAP (0, 5, 10 y 20 mM). 
En paralelo, ratones macho C57BL/6 en ayunas durante la noche se expusieron a una 
inyección intraperitoneal de APAP [0, 75, 150 y 300 (mg/kg)]. Se utilizaron ratones 
con deleción específica de hepatocitos de Xbp1 (Xbp1Δhepa) usando la recombinasa Alb-
CRE. Se usaron Xbp1-floxed (Xbp1f/f) como ratones de control. Todos los ratones se 
mantuvieron en ayunas durante la noche y se les administró una dosis subletal de APAP 
(>300 mg/kg) o vehículo. Veinticuatro horas más tarde, se sacrificaron los ratones y se 
recogieron tejidos y células. Se realizaron exámenes histopatológicos de hígados y 
células, inmunofluorescencia (IF) e inmunohistoquímica (IHC), Western Blot y 
estudios de qPCR en tiempo real y microscopía electrónica de transmisión (TEM). 
Resultados 
Los experimentos in vitro mostraron que una dosis superior a 10 mM o 300 mg/kg in 
vivo provocaba daño en las células del parénquima hepático (LPC), pérdida de la 
polaridad de los hepatocitos y activación de la respuesta de la UPR. La activación de 
UPR y JNK1/2 fue característica de la hepatotoxicidad mediada por APAP humana y 




Los ratones con deleción de Xbp1 en las células parenquimatosas hepáticas  mostraron 
una mortalidad significativamente menor a APAP que los compañeros de camada de 
flox. Los marcadores séricos de lesión hepática, focos necróticos, muerte celular, 
acumulación de lípidos, estrés oxidativo (por ejemplo: CYP2E1, 4HNE) e infiltración 
inmunitaria, inflamación y activación del inflamasoma se redujeron drásticamente en 
hígados de Xbp1∆hepa en comparación con ratones Xbp1f/f. Además, se encontró un 
aumento de la expresión de mRNA y proteínas de pIRE1α y la presencia de 
autofagosomas en animales Xbp1∆hepa, un fenómeno relacionado con la sobreexpresión 
de atg5 y pAMPK y la regulación negativa de P62. 
 
Conclusiones 
Nuestro estudio sugiere fuertemente que una dosis subletal de APAP indujo la 
activación del brazo IRE1α-XBP1, el aumento de especies reactivas de oxígeno (ROS) 
y la infiltración de citocinas inflamatorias, lo que finalmente condujo a la muerte de los 
hepatocitos y daño hepático. La ablación de Xbp1 en hepatocitos mejora el DILI 
derivado de APAP, evidenciado por una disminución de la expresión de JNK1/2, menos 
estrés oxidativo y activación del inflamasoma. Como resultado de la pérdida de Xbp1, 
la hiperactivación de IRE1α en los hepatocitos da como resultado la activación de la 
desintegración dependiente de IRE1 regulada (RIDD) y la supresión de la actividad del 
citocromo P450. Y la activación de la autofagia también se asocia con la protección 
contra la lesión hepática mediada por APAP. Nuestro estudio muestra una nueva 
perspectiva sobre la lesión hepática inducida por APAP y también proporciona la base 
para terapias clínicas dirigidas a la restauración de la función hepática después de una 










Drug-induced liver injury (DILI) is a leading cause of acute liver injury, including 
acetaminophen (APAP) overdose. Endoplasmic reticulum (ER) stress is an unexplored 
but very likely a triggering mechanism of APAP-induced liver injury. Under stress 
conditions, ER can initiate the unfolded protein response (UPR). However, the 
mechanisms of ER stress and UPR remain poorly understood. In this study, we overall 
aimed to unveil the relevance of the IRE1α-XBP1 arm, the most highly conserved arm 
of UPR, during APAP-induced acute liver failure (ALF) and provide the basis for 
therapeutic intervention.  
 
Methods 
HepaRGs were challenged with different concentrations of APAP (0, 5, 10&20 mM). 
In parallel, overnight fasted C57BL/6 male mice were challenged with an 
intraperitoneal injection of APAP [0, 75, 150&300 (mg/kg)]. Mice with hepatocyte-
specific deletion of Xbp1 (Xbp1Δhepa) using the Alb-CRE recombinase were used. Xbp1-
floxed (Xbp1f/f) were used as control mice. All mice were fasted overnight and given a 
sublethal dose of APAP (>300 mg/kg) or vehicle. Twenty-four h later, mice were 
sacrificed, tissues and cells collected. Histopathological examination of livers and cells, 
immunofluorescence (IF) and immunohistochemistry (IHC), Western Blot and Real 
time-qPCR studies and transmission electron microscopy (TEM) were performed. 
 
Results 
In vitro experiments showed that a dose greater than 10 mM or 300 mg/kg in vivo 
elicited liver parenchymal cells (LPC) damage, loss of hepatocyte polarity and 
activation of the UPR response. Activation of the UPR and JNK1/2 was characteristic 
of human and murine APAP-mediated hepatotoxicity. Ablation of Xbp1 in hepatocytes 
reduced APAP-induced hepatic damage. Mice with deletion of Xbp1 in liver 
parenchymal cells (LPC) showed significantly less mortality to APAP than flox 




oxidative stress (eg: CYP2E1, 4HNE) and immune infiltration, inflammation and 
inflammasome activation were dramatically reduced in livers of Xbp1∆hepa compared 
with Xbp1f/f mice. Furthermore, increased mRNA and protein expression of pIRE1α 
and presence of autophagosomes was found in Xbp1∆hepa animals, a phenomenon linked 
with atg5 upregulation and pAMPK overexpression and downregulation of p62. 
 
Conclusions 
Our study strongly suggests that a sublethal dose of APAP induced the activation of the 
IRE1α-XBP1 arm, the increase of reactive oxygen species (ROS) and the infiltration of 
inflammatory cytokines, ultimately leading to hepatocyte death and liver injury. The 
ablation of Xbp1 in hepatocytes ameliorates APAP-derived DILI, evidenced by 
decreased JNK1/2 expression, less oxidative stress and inflammasome activation. As a 
result of loss of Xbp1, hyperactivation of IRE1α in hepatocytes results in activation of 
regulated IRE1-dependent decay (RIDD) and suppression of cytochrome P450 activity. 
And the activation of autophagy is also associated with protection against APAP-
mediated liver injury. Our study shows a new perspective on APAP-induced liver injury, 
and also provides the basis for clinical therapies targeting the restoration of liver 





























Abbreviations Full Name 
ADRs Adverse drug reactions  
AIF Apoptosis-inducing factor 
ALF Acute liver failure 
ALT Alanine aminotransferase 
AMPK AMP-activated protein kinase  
ANGPTL3 Angiopoietin-like 3 
APC Antigen presenting cells  
APS Ammonium Persulfate 
APAP Acetaminophen  
APAP-AD APAP-Adducts  
ASK1 Apoptotic signal-regulated kinase-1 
AST Aspartate aminotransferase 
ATP Adenosine triphosphate 
ATF Activating transcription factor  
ATG Autophagy related gene 
BCRP Breast cancer resistance protein  
BIP Binding immunoglobulin protein 
BSA Bovine serum albumin 
BSEP Bile salt export protein  
Caspase Cysteine-dependent aspartate-directed protease 
CCK-8 Cell counting kit-8 
CC3 Cleaved caspase-3 
CCl4 Carbon tetrachloride 
cDNA Complementary DNA 
CHOP CCAAT-enhancer-binding protein homologous protein 
CSE1 Carboxylesterase 1 








DILI Drug-induced liver injury 
DMSO Dimethyl sulfoxide 
Δhepa Deleted in hepatocytes 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleoside triphosphate 
DTT Dithiothreitol 
eIF2α Eukaryotic initiation factor-2α 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
ERAD ER-associated protein degradation 
EtOH Ethanol 
FBS Fetal bovine serum 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GLDH Glutamate dehydrogenase 
GRP78 Glucose-regulated protein, 78 kDa 
GSK-3β Glycogen synthase kinase-3β 
GSH Glutathione 
H&E  Hematoxylin and eosin 
HMGB1 High mobility group-1 
HRP Horseradish peroxidase 
H2O2 Hydrogen peroxide  
HO-1 Heme oxygenese-1  
HSCs Hepatic stellate cells  






IL-1α Interleukin-1α  
IL-1β Interleukin-1β  
IL-18 Interleukin-18 
IP Intraperitoneal injection 
iNOS Inducible nitric oxide synthase  
IRE1α Inositol-requiring enzyme 1-α 
JNK c-Jun NH2-terminal kinase 
KCs Kupffer cells  
LC3 Light chain-3 
LDH Lactate dehydrogenase 
LIR LC3-interaction region  
LPC Liver parenchymal cells  
LSECs Liver sinusoidal endothelial cells 
MAPK Mitogen-activated protein kinase 
MAP2K Mitogen-activated protein kinase kinase 
MAP3K Mitogen-activated protein kinase kinase kinase 
MgCl2 Magnesium chloride 
MKK4 MAP kinase kinase-4 
MLK3 Mixed lineage kinase-3 
MMP Mitochondrial membrane potential  
MPT Mitochondrial permeability transition 
mRNA Messenger RNA 
mTOR Mammalian target of rapamycin 
NADPI N-acetyl-p-benzoquinone imine 
NAC N-Acetylcysteine  
NAFLD Non-alcoholic fatty liver disease 




NTCP The sodium-taurocholate co-transporting polypeptide  
NF-κB Nuclear factor kappa-B 
NO Nitric oxide  
OATP The organic anion transporting polypeptide 
OAT The organic anion transporter 
OCTNs Organic cation transporters  
OD Optical density 
ORO Oil Red O  
PBS Phosphate buffered saline 
PBST Phosphate buffered saline supplemented with Tween 20 
PCR Polymerase chain reaction 
PDI Protein disulfide isomerase-A1 
PE Phosphatidylethanolamine  
PERK The protein kinase RNA -like ER kinase 
PFA Paraformaldehyde 
P-gp P-glycoprotein 
PKC Protein kinase C  
RER Rough endoplasmic reticulum  
RIDD Regulated IRE1-dependent decay  
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT Reverse transcription 
O2•- Superoxide anion  
SDS Sodium dodecyl sulphate 
SER Smooth surface endoplasmic reticulum 
SMA Smooth muscle actin 
SULTs Sulfotransferases  
TAE Tris Acetate EDTA Buffer 




TBS Tris buffered saline 
TBST Tris buffered saline supplement with Tween 20 
TEMED N ,́N,N ,́N -́Tetramethyl diamine 
TEM Transmission electron microscopy 
TG Hepatic triglyceride 
TJs Tight junctions  
TLR Toll-like receptors  
TMRM Tetramethylrhodamine, methyl ester 
TNF-α Tumor necrosis factor-α 
TRAF2 TNF receptor associated factor-2 
Tris 2-Amino-2 (hydroxymethyl)-1,3-propandiol 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
Tween 20 Polyoxyethylene (20) Sorbitan Monolaureat 
UBA Uubiquitin-associated domain  
UCM Complutense University 
UGTs UDP-glucuronosyltransferases 
ULK1 Unc-51 like autophagy activating kinase-1 
UPR Unfolded protein response  
XBP1 X-box binding protein-1 




































3.1 Anatomy, physiology and function of the liver 
The liver is a dynamic and heterogeneous organ, and controls numerous 
physiological processes, including the production of bile, regulation of plasma 
proteins and glucose, and biotransformation of drugs and toxins. The liver is involved 
in the maintenance of the whole homeostasis as an active, bidirectional biofilter (1). 
It filters the portal blood that transports nutritional and toxic compounds from the 
environment through the gastrointestinal tract and it also filters the systemic blood, 
thus providing the only way to remove non-water-soluble substances. It also rapidly 
metabolizes most nutritional compounds, and neutralizes and removes toxic 
exogenous and endogenous materials (2).  
The liver is also a unique organ in that it is supplied by both arterial and venous 
blood. The hepatic artery carries oxygen-rich blood from the aorta via the celiac trunk, 
whereas the portal vein carries blood rich in digested nutrients from the entire 
gastrointestinal tract and from the spleen and pancreas. All the blood in the liver ends 
up in the sinusoids, and is collected by the hepatic veins, then reaches the systemic 
circulation via the inferior vena cava (3). 
The liver is composed of several cell types of different origin including 
hepatocytes, biliary epithelial cells (cholangiocytes), hepatic stellate cells (HSCs), 
Kupffer cells (KCs) and liver sinusoidal endothelial cells (LSECs) (4). All of these 
cells in the liver function cooperatively and regulate hepatic function at multiple 
levels. The basic functional unit of the liver is the hepatic lobule, consisted of chords 
of hepatocytes, the hepatic artery, portal vein and bile ducts (5). The terminal branch 
of the hepatic vein is in the center of the hepatic lobule, and hepatocytes are arranged 
radially around the central vein to form hepatic cords. The sinusoids are among the 
hepatic cords. The corners of the lobule are occupied by the portal triads. The portal 
triads of the normal liver are distributed regularly in the histological structure, and 





Figure 1. Diagrammatic representation of a liver lobule and its vascular network. On 
the edge of the lobule, portal triads containing three vessels (bile duct, portal vein and hepatic 
artery) are arranged, and a central vein is placed on the center of the lobule. Branches of the 
hepatic artery and portal vein are located on the periphery of the lobule, and the blood from 
hepatic artery and portal vein both perfuse the sinusoids. Bile ducts located peripherally drain 
the bile canaliculi that run between the hepatocytes (6). 
 
3.1.1 The classification and function of liver cells 
3.1.1.1 Parenchymal cells 
The hepatocytes are the most crucial parenchymal cells of the hepatic tissue and 
the primary epithelial cell population of the liver, representing about 60% of all cells 
in the parenchymal matrix and making up the majority of the liver volume (around 
80%) (7). Hepatocytes are shaped as complex rhomboids with several distinct 
surfaces and the nuclear is in the middle of the cells (8). The hepatocyte is the main 
site that manufactures serum albumin, lipid protein, fibrinogen and the prothrombin 
group of clotting factors. It also forms fatty acids from carbohydrates and synthesizes 
triglycerides from fatty acid and glycerol (9). According to molecular specialization 
of their various surface membranes in the forms of receptors, pumps, transport 
channels and carrier proteins, there are three functionally distinct domains. 




compounds such as drugs and endogenous compounds such as steroids through the 
developed smooth endoplasmic reticulum (SER) (10). 
3.1.1.2 Non-parenchymal cells 
LSECs are the highest proportion of non-parenchymal cells in the liver, and its 
fenestration structure and high capacity of clearance plays an indispensable role in 
the physiological and pathological processes of the liver. LSECs mainly regulate the 
occurrence and development of liver disease through anti-inflammatory, endocytosis 
clearance, hepatic sinusoidal capillarity, secretion of pro-angiogenic signal factors 
and maintenance of HSCs (11). LSECs adjust the material exchange and information 
exchange inside and outside the liver sinusoids by changing the diameter and the 
number of holes in the LSECs (12). LSECs also play an important role in plasma 
ultrafiltration and liver microcirculation. There are three endocytosis receptors in 
LSECs: hyaluronan/scavenger receptor, collagen-α-chain/mannose receptor and 
Fc γ-receptor Iib2. Hyaluronic acid/scavenger receptors include SR-A, SR-B (SR-B1 
and CD36) and SR-H (stabilin-1 and stabilin-2), among which SR-H is the main 
scavenger receptor for LSECs. LSECs can swallow a large amount of exogenous and 
endogenous substances, and remove soluble macromolecules and some particles with 
a diameter of less than 0.5 μm from the blood (13).  
HSCs are located in the Disse space and account for 30% of nonparenchymal 
cells, which is a key factor in the development of liver fibrosis (14). It is close to 
sinusoidal endothelial cells and hepatocytes, and distributes numerous roots around 
the hepatic sinusoids. Under normal circumstances, HSCs participate in the 
metabolism and storage of Vit A and the synthesis and degradation of extracellular 
matrix, and express cytokines and receptors. Once liver damage, HSCs are activated 
as a result of the collaboration of paracrine and autocrine effects of many cytokines. 
Stellate cells become activated myofibroblast-like cells and keep on proliferation. The 
cells become bigger, vitamin A lipid droplets disappear, and the secretion of collagen 
fibers and other extracellular matrix increases. The expression of α-Smooth muscle 
actin (SMA) is a sign of HSC activation. Studies have shown that the activated HSCs 




sinusoidal pressure through cell contraction, which ultimately laid the pathological 
basis for liver fibrosis and portal hypertension (15). 
The cholangiocytes, also named biliary epithelial cells, comprising less than 1% 
of the total number of cells in the liver parenchyma, form the channels of the biliary 
system, produce bile and modify the composition of the bile (16). Besides, the 
cholangiocytes also play an important role in immunoregulation. The cholangiocytes 
not only tackle the microorganism, xenobiotics and foreign antigens in the biliary 
tract, but also produce antibacterial products, like defensins, lysozyme and transport 
IgA, and express MHC class I and II molecules and antigen presenting cells (APC) 
(17). 
Due to the exposure to a variety of viruses, bacteria, parasites and tumor cells, 
the liver contains a large amount of lymphocytes of different phenotypes and the 
macrophages (18). Hepatic macrophages can be divided into two classes based on 
their origin, bone marrow-derived macrophages and resident macrophages (19). The 
Kupffer cells are the resident macrophages in the liver, and perform the 
immunoregulatory function, which makes the liver as the largest organ in the immune 
system with the presence of almost all subtypes of lymphocytes and dendritic cells.  
3.1.2 The metabolism of drugs in the liver 
The liver is one of the main organs of drug metabolism and elimination in the 
body. Drugs enter the liver and undergo a series of processes under the action of 
multiple drug-metabolizing enzymes, which is called biotransformation or drug 
metabolism (20). There are two results after biotransformation of the drugs in the 
body: one is inactivation, becoming a drug without pharmacological activity; the 
other one is activation, from pharmacological inactivity to pharmacologically active 
metabolites or toxic metabolites, or remaining the original pharmacological effects 
after metabolism (21, 22). 
3.1.2.1 Drug transporters in the liver 
It is thought that drugs are taken into the hepatocytes via passive diffusion across 
the basolateral hepatocyte membrane for a long time, but then this concept was 




mediated, sodium-dependent process (23). Fat-soluble compounds can pass through 
the lateral membrane of the bile duct by passive diffusion, while organic compounds 
in polar or ionic form, such as cyclosporine and statins (24), need to be transferred 
into hepatocytes with the assistance of transporters. Drug transporters are functional 
proteins located on the cell membranes, and the loss or inhibition of its functions is 
the main cause of drug interaction and certain diseases (25). The uptake transporters, 
including the sodium-taurocholate co-transporting polypeptide (NTCP) (26), the 
organic anion transporting polypeptide (OATP) (27), the organic anion transporter 
(OAT) (28) and carnitine/organic cation transporters (OCTNs) (29), are located on 
the sinusoid membranes, and affect the concentration and metabolism of the drugs in 
the liver. After the drug enters the liver, it is metabolized by abundant drug-
metabolizing enzymes, then excreted from the liver with the help of efflux 
transporters, such as P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) 
and bile salt export protein (BSEP), in the form of prototype or its metabolites (30-
32). Otherwise, the drugs or its metabolites can also pass through the efflux 
transporters in the lateral membrane of hepatocytes, and return to the systemic 
circulation. 
Although transporters do not have the ability to metabolize drugs, 
transmembrane transport mediated by them is the rate-limiting step. Only the drug 
entering the hepatocytes can be catalyzed by phase I or II metabolic enzymes and 
generate the metabolites (33, 34).  
3.1.2.2 Biotransformation of drugs 
The concentration of a drug, especially when administered orally, is greatly 
reduced before it reaches the systemic circulation, which called the first pass effect 
(35). It is due to the process of absorption happened in the liver and gut wall. Once 
drugs enter the blood, they enter the liver through the portal vein, and most drugs 
undergo varying degrees of structural change in the liver, including oxidation, 
reduction, decomposition and combination. After metabolism, its pharmacological 
effects are weakened or diminished. Only a few drugs are metabolized and have a 




The liver is rich in various enzymes required for phase I and phase II metabolism 
(20). Phase I metabolism are mainly oxidation, reduction and decomposition 
reactions. After phase I metabolism, the drugs may have some polar groups such as 
cholesterol and oxides, but can exhibit very different pharmacological actions. 
Oxidation reactions are the most common phase I reactions. Monooxygenase is one 
of the most important enzymes for oxidizing heterologous substances, and mainly 
located in the microsomes of the smooth endoplasmic reticulum, including 
cytochrome P450 (CYP450), NADP+ and NADPH reductase (37). CYP450 enzymes 
can be divided into different categories according to the similarity of amino acid 
sequence. The most important enzymes in the human are CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and 
CYP3A5 (38). CYP450 enzymes have obvious differences among species, and the 
metabolic pathways and metabolites of drugs in animals and humans may be also 
different. Polymorphism is an important feature of CYP450 enzymes, and an 
important reason for individual differences in drug reactions (39). The so-called 
polymorphism refers to the large difference in the number of certain P450 enzymes 
between different individuals of the same genus. The individual having a large 
number of enzymes have a faster metabolic rate, which is called a broad metabolizer 
(40). 
The activated CYP450 contains a heme-iron center. The iron binds to proteins 
through cysteine thiolate ligands. These cysteine ligands and several flanking residues 






Figure 2. Mechanism of action of cytochrome P450. This scheme is a simplification of the 
mechanism of action of cytochrome P450 (CYP450). In it, Fe3+ represents iron from the heme 
group of oxidized CYP, RH and ROH substrates and products respectively. In this oxide-
reduction cycle superoxide anion (O2•-) and hydrogen peroxide (H2O2) are released (41).  
 
A large number of drugs are metabolized by CYP enzymes, which inevitably 
leading to the competitive binding of the drug to the active site. This can be illustrated 
by the interaction between the central muscle relaxant tizanidine and the selective 
serotonin reuptake inhibitor fluvoxamine (42). Besides, many drugs can affect the 
activity of CYP enzymes through inducing isoenzymes biosynthesis or directly 
inhibiting the activity of CYP enzymes. A typical example is phenytoin, which could 
induce CYP1A2，CYP2C9，CYP2C19 and CYP3A4 (43). When applying two or 
more drugs at the same time, one drug could change the metabolism of other drugs, 
leading to the change of plasma concentration. These drug-drug interactions at the 
level of the metabolizing enzyme are potentially dangerous, and the main source of 
adverse drug reactions (ADRs) (44). Therefore, considering these drug interactions, 
dose adjustment or selection of drugs that do not interact with CYP enzymes need to 
be required, especially using drugs that are vital to the patients.  
3.2 Drug-induced liver injury (DILI) 
DILI is defined as a chemical insult resulting in injury to the liver (45). 
Nowadays, DILI is one of the most common and serious ARDs (46), and is a leading 
reason for drug withdrawal and the high attrition rates in drug development (Table 




hypersensitivity to the compound. A wide variety of drugs can cause DILI, including 
anti-tumor chemotherapy drugs, anti-tuberculosis drugs, antipyretic analgesics, 
immunosuppressive agents, hypoglycaemic therapies, or anti-bacterial, anti-fungal 
and antiviral drugs. DILI leads to multiple presentations in the clinic, including 
elevated liver enzymes, hepatitis, hepatocellular necrosis, cholestasis, fatty liver and 
liver cirrhosis. In some patients, liver injury is easily detected by blood tests. However, 
in some patients, the clinical symptoms are not specific and hard to distinguishable 
from other hepatic diseases.  
Table 1. The incidence of drug-induced liver injury (47) 
 
DILI can be divided into two subtypes according to the drug hepatotoxicity: 
“intrinsic” and “idiosyncratic”. The former refers to dose-dependent hepatotoxicity 
that is predictable in humans or animal models, while idiosyncratic DILI (iDILI) is 
an unpredictable injury that cannot be explained by the known pharmacological 
properties (48). Most DILI cases are idiosyncratic and become a major problem in 
the development of new medications (49, 50). 
Acetaminophen, also known as paracetamol, has already became the most 
commonly used antipyretic and analgesic drug since 1955 (51). Up to now, 
acetaminophen still takes up an important position in clinical medicine. The use of 
APAP is normally believed to be safe at therapeutic doses. The main indications are 
fever caused by cold, as well as migraine, neuralgia, arthralgia and postoperative pain. 
In the more than half a century using APAP to fight against diseases, people also 
suffer from the adverse reactions caused by it. It has been found that APAP has 
varying degrees of influence on the digestive system, respiratory system and blood 




Long-term or overdose will cause liver damage, even acute liver failure (ALF) (52). 
In the United Kingdom, APAP-induced liver injury accounts for 57% of ALF cases 
(53), and the number is 39% in the United States (54). Every year, around 30,000 
patients are admitted to the hospital in the United States due to APAP hepatotoxicity. 
Although some symptoms are mild, such as hepatitis, cholestasis and asymptomatic 
transaminase elevation, up to 48% of patients are still diagnosed with ALF (55, 56). 
According to papers published, the research on liver injury caused by APAP 
began in 1966. However, despite half a century of research, the specific mechanism 
of APAP hepatotoxicity is still not fully explained, and clinical treatment is limited. 
It is generally believed that APAP toxicity is caused mainly by the excess formation 
of the reactive intermediate, N-acetyl-p-benzoquinone imine (NAPQI), which is 
generated by oxidation of APAP by CYP450-dependent metabolism (57, 58).  
When APAP enters into the body, only a small part is excreted in urine in the 
form of a prototype, and almost 90% is metabolized to non-toxic conjugates through 
UDP-glucuronosyltransferases (UGTs) or sulfotransferases (SULTs), then excreted 
from the urine (59, 60) (Fig. 3). At therapeutic doses, NAPQI can be quickly 
detoxified by combining with cysteine and thiol uric acid or regenerating non-toxic 
APAP. At a toxic dose, a large amount of NAPQI is produced, which results in its 
robust reaction with hepatic glutathione stores and subsequently saturates the 
detoxification pathway and leads to the depletion of glutathione (GSH). The 
excessive amounts of NAPQI is available for reaction with protein sulfydryl groups 
to form APAP protein adducts, thereby resulting in increased oxidative stress and 
hepatocyte damage (61). Moreover, the accumulated NAPQI further combine with 
biological macromolecules inside and outside the cell membrane and cause the 






Figure 3. Acetaminophen (APAP) metabolic pathways. When consumed at therapeutic 
doses, the majority (80%–90%) of APAP is conjugated with glucuronic acid or sulfate and 
excreted through the kidneys. A minor component is acted upon by cytochrome P450 
(CYP450) enzymes such as CYP2E1 and CYP1A2 to form a reactive metabolite, N-acetyl-
p-benzoquinone imine (NAPQI). Though highly reactive, NAPQI is rarely harmful after 
consumption of therapeutic doses because it is rapidly conjugated with abundant glutathione 
stores in the liver and excreted through the bile (63).  
 
Metabolism of APAP can be influenced by genotype differences. Due to the 
polymorphism of the UGT enzyme, variations in glucuronidation have been observed 
in different populations. Recently, it has been demonstrated that the concentration of 
APAP protein adduct is higher in UGT2B15*2/*2 genotype subjects than 
UGT2B15*1/*2 and UGT2B15*1/*1 individuals (64). In fact, protein adducts can be 
detected in the vast majority of people taking therapeutic doses of APAP (65), and 
protein adducts are formed before significant GSH depletion (60, 66, 67). Rather than 
assessing the formation of protein adducts in cells, which were initially considered to 
be critical for cell death (68), it is better to assess that the effect of protein adducts 
formation on mitochondrial proteins, which is most correlated with toxicity (69, 70). 
At present, the traditional serum biomarker cannot meet the requirements for 
early detecting DILI. Several new biomarkers have been reported, including 
apoptosis-related caspase cleaved keratin 18 (cCK18), necrosis-related HMGB1and 
microRNA (especially microRNA-122), specific mitochondrial injury biomarker 




well as genetic biomarkers reflecting the susceptibility to DILI, such as the genetic 
polymorphisms of HLA, drug metabolizing enzymes and drug transport proteins (47). 
Some of these biomarkers are already being used in early clinical trials. Though 
current biomarkers are not specific to DILI and their value for clinical use still needs 
to be widely verified, their addition to conventional measurements could soon 
transform DILI prediction and detection, thereby promoting earlier treatment. 
The therapy for acetaminophen-induced liver injury is mainly supportive 
treatment, and the common recognized specific antidote is N-acetylcysteine (NAC). 
On the one hand, NAC supplements and maintains the liver GSH by providing 
cysteine, on the other hand, it can also provide raw materials for the synthesis of 
sulfonic acid group to enhance the sulfonated metabolic pathway. Besides, NAC can 
also prevent the oxidization of thiol group on the molecule by NAPQI (71). However, 
the incidence of allergic reactions is high in intravenous injection, and NAC is 
contraindicated in patients with coma, pancreatitis, intestinal obstruction and 
gastrointestinal insufficiency (72). Additionally, it is recommended to use NAC 
within 12 h after acute APAP poisoning. The longer the injury time, the worse the 
detoxification effect is (73). Therefore, more effective treatments of APAP-induced 
injury are urgently needed. 
3.3 The mechanism of acetaminophen (APAP)-induced liver injury 
The mechanisms of APAP-induced liver injury are complicated, and nowadays 
the release of inflammatory cytokines, mitochondrial dysfunction and endoplasmic 
reticulum (ER) stress are recognized as main causes of APAP-induced liver injury 
(74, 75).  
3.3.1 Reactive oxygen species (ROS) and oxidative stress 
Oxidative stress is the result of the generation of ROS, which are a by-product 
of normal metabolism and have roles in cell signaling and homeostasis. Oxidative 
stress in acetaminophen toxicity is triggered by the formation of cellular superoxide 
or its dismutation, resulting in the formation of increased hydrogen peroxide through 
a variety of mechanisms, including the uncoupling of CYP450 or other enzymes from 




results in increased intracellular peroxide levels and increased oxidative stress 
through the Fenton mechanism. This mechanism involves the reduction of peroxides 
by ferrous ions to the formation of highly reactive hydroxyl radicals, which can in 
turn lead to lipid peroxidation and the oxidation of proteins and nucleic acids (79).  
The discovery of nitric oxide (NO) as an important signaling molecule has given 
people a deeper understanding of the mechanism of oxidative stress. Oxidative stress 
includes not only the classic Fenton mediated mechanism, but also nitric oxide. 
Enhanced production of superoxide radicals (O2·‐) reacts with nitric oxide (NO), 
produced by inducible nitric oxide synthase (iNOS), forming peroxynitrite (ONOO‐) 
(80). The effects of iNOS on the liver have been studied in rats and mice. Gardner 
and colleagues (81) reported that a toxic dose of acetaminophen to rats can induce 
iNOS in centrilobular hepatocytes. The development of toxicity is related to the 
expression of iNOS. In addition, treatment of rats with iNOS inhibitor can reduce 
liver toxicity. The highly reactive and potent oxidant ONOO‐ causes nitration of 
protein tyrosine residues (82) which induces damage to mitochondrial DNA and the 
opening of the mitochondrial membrane pore. 
The mechanism of the increase of reactive oxygen/nitrogen species in the 
toxicity of APAP has been extensively studied. Three different mechanisms have 
been proposed to explain the increase of reactive oxygen levels: uncoupled CYP2E1 
or other enzymes (83), activated NADPH oxidase (78) and mitochondrial uncoupling 
(76). Through each mechanism, it can be foreseen that increased superoxide (O2
.-) 
production is a key event. The increased level of superoxide can lead to an increase 
in the formation of hydrogen peroxide and peroxynitrite (ONOO-) in cells. 
However, mitochondrial oxidative stress alone is not sufficient to ultimately 
trigger cell death. A number of molecules have been found to participates in the 
regulation of APAP-induced oxidative stress, such as c-Jun N-terminal kinases (JNK) 
and the nuclear erythroid-2-related factor 2 (Nrf2), which may serve as potential 
therapeutic targets (84). JNK is a family of serine/threonine kinase belonging to the 
mitogen-activated protein kinases (MAPKs) family, and plays a conclusive role in 




unraveling not only synergistic and protective actions of JNK1 and JNK2 in 
hepatocytes, but also that specific signaling cascades might be activated in other cell 
types (e.g. immune cells), and aggravate the course of DILI. Phosphorylation of JNK 
occurs early after APAP overdose and is mediated by MAP kinase kinases (MAP2Ks), 
which in turn are activated by MAP kinase kinase kinases (MAP3Ks) (29). The best 
characterized MAP3Ks are apoptosis signal-regulating kinase-1 (ASK1) and mixed-
linage kinase 3 (MLK3). The oxidation of thioredoxin due to oxidative stress causes 
ASK1 to dissociate from its binding partner and then be activated. MLK3, a member 
of the Ser/Thr protein kinases family, mediates the initial phase of JNK activation 
(87). Glycogen synthase kinase 3β (GSK-3β) is also involved in the early-phase of 
JNK activation. Inhibition of GSK-3β in mice prevents JNK activation and 
ameliorates APAP-derived toxicity (88). The MAP2Ks, including mitogen-activated 
protein kinase kinase (MKK) 4 and MKK7, are capable of phosphorylating JNKs at 
Thr/Tyr residues (89). Furthermore, MKK4 activates both JNK and p38 and MKK7 
activates only JNK (90). A feedforward self-sustaining signaling pathway referred as 
the JNK amplification loop (91, 92) would maintain sustained JNK activation, 
directly leading to liver damage and dysfunction. Activated JNK (p-JNK) translocates 
to mitochondria and binds to the Sab protein on the outer mitochondrial membrane 
(93, 94), impairing mitochondrial respiration and enhancing the release of ROS (95). 
ROS release, in turn, activates ASK1 and MKK4, which sustains JNK activity and 
amplifies the toxic effect (Fig. 4). 
3.3.2 Mitochondrial dysfunction 
Electron microscope examination of APAP-treated liver by the Racz laboratory 
indicated the changes of the mitochondrial morphology (96). Jollow et al. reported 
that the mitochondria is the target of acetaminophen reactive metabolites (68), and 
many arylated proteins have been found in mitochondria (97). Functional changes in 
the ability to chelate calcium have been reported (98). In isolated rat liver cells and 
in vivo, mitochondrial respiration is inhibited in complex I and II, but not in complex 
III (99-101). In addition, adenosine triphosphate (ATP) levels in the body and treated 




changes (102). The laboratories of Moldeus and Orenius reported that adding NAPQI 
to isolated rat liver mitochondria caused the release of chelated Ca2+ (103). 
Given a toxic dose of APAP, superoxide anions are produced which increase 
ROS accumulation through a variety of mechanisms (104, 105). Free radical 
metabolites participate in the redox process and are capable of inducing cell damage 
and abnormal protein expression. The amplification of mitochondrial oxidative stress 
can reduce the synthesis of mitochondrial proteins and increase mitochondrial 
permeability transition (MPT), which increase mitochondrial membrane permeability 
(106) and lead to the collapse of the mitochondrial membrane potential (MMP). The 
mitochondria then swell, rupture and release proteins from the intermembrane space 
(107), a sequence implicated in cell death pathways such as apoptosis (108). 
Excessive APAP causes a series of toxic events such as mitochondrial respiratory 
depression, ATP depletion and mitochondrial oxidative stress (109). 
According to reports, MPT inhibitors can block the toxicity of APAP in vitro 
and in vivo. Kon and colleagues (110) showed that cyclosporine A and the non-
immunosuppressive Cyclosporine A analog NM811 inhibited the toxicity of APAP 
in cultured mouse liver cells. Cyclosporine A does not change the glutathione 
depletion caused by APAP, which indicated that inhibiting the metabolism of APAP 
to NAPQI could not prevent toxicity. Reid and his colleagues (111) studied the effects 
of MPT inhibitors in freshly isolated mouse liver cells (112, 113). In these studies, 
hepatocytes were incubated with APAP for 2 h, then washed out the APAP and 
incubated with medium alone. This method clearly separated direct metabolism from 
those occurring downstream of APAP metabolism. Toxicity occurred during the 
reincubation phase (3-5 hours). Adding MPT inhibitor or NAC during the 
reincubation stage could completely suppress toxicity. Through 
tetramethylrhodamine methyl ester (TMRM) and fluorescence analysis, it was shown 
that the loss of mitochondrial membrane potential caused by APAP can be prevented 
by adding MPT inhibitor and NAC during the reincubation period. 
Necrosis is mediated by the opening of MPT pores in the inner mitochondrial 




caused by the opening of holes or channels in the outer mitochondrial membrane. It 
is believed that the pore releases pro-apoptotic factors, including cytochrome C, 
endonuclease G, Smac/Diablo, and apoptosis-inducing factor (AIF) from the cell 
membrane space into the cytosol (114, 115) (Fig. 4).  
The phosphorylated JNK as a result of oxidative stress translocates to the 
mitochondria and binds to Sab on the outer mitochondrial membrane, thereby further 
inhibiting the transport of mitochondrial electrons through the Src-mediated pathway 
(116). The development of mitochondrial apoptosis-induced pathways seems to be 
sensitively regulated by Bcl-2 family proteins and is composed of pro-apoptotic 
proteins (eg: Bax) and anti-apoptotic proteins (eg: Bcl-2). In particular, the pro-
apoptotic protein Bax is usually in the cytosol. Activation causes Bax to translocate 
to the mitochondria, insert into the outer membrane, and oligomerize to form channels 
(117-119). Apoptotic proteins were released from these channels (120). Whether 
hepatocytes die due to necrosis or apoptosis, the relative content of ATP seems to be 
an important factor. Low ATP levels are associated with necrosis, while adequate 
ATP levels contribute to cell apoptosis. It’s showed that cultured mouse hepatocytes 
died mainly due to necrosis after APAP challenge. However, adding fructose (a 
glycolytic substrate for ATP production) and glycine (a membrane stabilizer) into the 






Figure 4. The mechanism of hepatocyte death induced by acetaminophen (APAP). At 
high concentrations of acetaminophen, components of the electron transport chain (such as 
ATP synthase) are affected, which disrupts the function of the respiratory chain and enhances 
the production of free radicals (such as superoxide). It reacts with nitric oxide (NO) in the 
mitochondria to form highly reactive nitrite, which weakens the mitochondria’s antioxidant 
defense capabilities, leading to mitochondrial oxidative stress and the oxidation of proteins, 
such as mitochondrial thioredoxin. In the cytosol, the phosphorylated JNK translocates to the 
mitochondria and binds to Sab on the outer mitochondrial membrane, thereby further 
inhibiting the transport of mitochondrial electrons through the Src-mediated pathway. These 
events activate mitochondrial permeability transition and release mitochondrial inner 
membrane proteins, such as endonuclease G and apoptosis inducing factor (AIF), as well as 
cytochrome c and Smac, eventually leading to cell death (116).  
 
3.3.3 Unfolded protein response (UPR) and endoplasmic reticulum (ER) stress 
ER is the major cellular site of protein folding and modification, and made up of 
two subunits - rough ER (RER) and smooth ER (SER). The two types of ER share 
many of the same proteins and engage in certain common activities such as the 
synthesis of certain lipids and cholesterol. ER stress occurs when the amount of 
protein entering the ER exceeds its folding capacity. ER stress and the activation of 
UPR are associated with multiple liver diseases, including DILI. ER stress is induced 
late after APAP intoxication (a sublethal dose of over 300 mg/kg) in murine models, 
and becomes significant 12 h following APAP administration (122). There are some 




occurrence of microsomal alterations secondary to NAPQI generation. APAP 
induced GSH depletion, lipid peroxidation and an oxidative shift of the ER 
oxidoreductases Erp72 and protein disulfide isomerase (PDI) in liver microsomes 
(123). Moreover, NAPQI could bind with several microsomal proteins such as PDI 
and calreticulin, which play a major role in protein folding and calcium concentration 
within the ER (124). The other hypothesis is that ER stress might be the secondary 
consequence of mitochondrial dysfunction (125).  
Under stress conditions, the ER initiates UPR to restore the balance. The UPR 
contains three signaling arms: inositol-requiring enzyme 1 (IRE1α), the protein 
kinase RNA-like ER kinase (PERK) and activating transcription factor 6 (ATF6) 
(126). These signaling pathways increase ER capacity, degrade misfolded proteins, 
reduce the synthesis of new protein entering the ER, and ultimately restore ER 
homeostasis. IRE1α is an ER transmembrane protein and maintained in an inactive 
state through binding to the glucose-regulated protein 78 kDa (GRP78), also known 
as binding immunoglobulin protein (BIP), in non-stressed cells. Upon APAP-
mediated ER stress, IRE1α initiates splicing of the message RNA (mRNA) encoding 
X-box binding protein 1 (XBP1) and translocates to the nucleus, triggering an 
inflammatory response and promoting apoptosis mediated via ASK1 and JNK (127). 
Among the JNK apoptosis-inducing substrates, Bcl-2 and Bim are inhibited and 
activated by JNK phosphorylation, respectively (128, 129). If the stress is not relieved, 
a downstream transcription repressor of UPR, CCAAT-enhancer-binding protein 
homologous protein (CHOP), is activated (130). P38, one member of MAPK, 
phosphorylates and activates the transcription factor CHOP, thereby causing changes 
in gene expression that are conducive to apoptosis, including increasing the 
expression of Bim and DR5, while reducing the expression of Bcl-2 (131, 132). 
CHOP expression has been shown to sensitize cells to apoptosis (133). Dot and Uzi 
showed in their research that CHOP KO mice were protected from APAP induced 
damage and exhibited decreased liver necrosis and increased survival (122). All these 
data implicate that the arm of IRE1α- XBP1 plays a critical role in the APAP toxicity. 




encoding membrane proteins and secreted proteins through a process termed 
regulated IRE1-dependent decay (RIDD), which may have effects on the adaptive 
survival under ER stress. The RIDD process selectively targets and degrades mRNA 
encoding proteins involved in protein folding. Hur reported that in genetically deleted 
XBP1 mice, constitutive IRE1α hyperactivation in hepatocytes resulted in reduced 
JNK activation and protection from APAP through activation of RIDD and 
suppression of cytochrome P450 activity (134). However, the detailed mechanism of 




Figure 5. Unfolded protein response (UPR) pathways in the endoplasmic reticulum (ER) 
stress. The increase of misfolded or unfolded proteins in the ER lumen triggers ER stress-
mediated UPR, which has three different effectors: the protein kinase RNA-like ER kinase 
(PERK), the activating transcription factor 6 (ATF6) and the inositol-requiring enzyme 1 
(IRE1). Under ER Stress, IRE1α initiates splicing of the mRNA encoding X-box binding 
protein 1 (XBP1), PERK phosphorylates eukaryotic initiation factor 2α (eIF2α) and ATF6 is 
cleaved (clv. ATF6) and translocates to the nucleus, triggering apoptosis. IRE1α also recruits 
tumor necrosis factor (TNF) receptor associated factor 2 (TRAF2) and apoptosis signal-
regulating kinase 1 (ASK1) to mediate the activation of c-jun N-terminal kinase (JNK) and 
nuclear factor kappa B (NF-κB) pathways, and regulates gene expression through regulated 
IRE1α-dependent decay of mRNA (RIDD)-mediated mRNA decay (135).  
 
3.3.4 Sterile inflammation 
Extensive cell necrosis after APAP overdose can lead to the release of damage-




fragments and high mobility group-1 (HMGB1) protein (75, 136, 137). DAMP binds 
to pattern recognition receptors on inflammatory cells, such as toll-like receptors 
(TLR), and transcriptionally activates cytokines (138, 139). Some of these 
inflammatory mediators have constitutive activity, such as tumor necrosis factor α 
(TNFα) and interleukin-1α (IL-1α), while others are produced as precursors that 
require proteolytic cleavage, such as interleukin-1β (IL-1β) and interleukin-18 (IL-
18) (138). The pro-inflammatory cytokines and chemokines can activate neutrophils 
and monocytes, and recruit these cells into the liver, which may aggravate existing 
liver injury (139). Although it is generally believed in the literature that APAP-
induced cell necrosis will lead to the release of DAMPs, the formation of pro-
inflammatory mediators and the recruitment of inflammatory cells to the liver, the 
effect of sterile inflammation is controversial. The first controversy is whether 
neutrophils, the first responder to the initial cell death, cause the damage. The main 
support for this hypothesis comes from research that shows that neutropenia has a 
protective effect on APAP hepatoxicity (140). However, long-term neutropenia can 
lead to a preadaptation effect, which is protective independent of the actual neutrophil 
(141). In addition, inactivating neutrophils by inhibitor or the use of knockout mice 
cannot resist APAP-induced liver damage (142, 143). In human patients, no 
neutrophil activation or neutrophil-mediated oxidative stress was observed (144). In 
short, these findings strongly oppose the direct involvement of neutrophils in the 
injury. The second controversy is the role of certain proinflammatory mediators, 
especially IL-1β. It is reported that DNA fragments can promote the formation of pro-
IL-1β. The Nalp3 inflammasome is activated, leading to the activation of caspase 1, 
and processing pro-IL-1β into active cytokine (145). However, caspase inhibitors can 
prevent the formation of IL-1β but cannot protect against APAP toxicity, and adding 
high doses of exogenous IL-1β can enhance the recruitment of neutrophils, but will 
not affect APAP-induced liver damage (146). Recently, another study showed that 
mice deficient in IL-1β, caspase 1 or Nalp3 have no protection against APAP 
hepatotoxicity (147), indicating that inflammasome activation and IL-1β formation 




colleagues suggested that IL-1α plays a role in pathophysiology. IL-1α is produced 
by KCs through toll-like receptor (TLR) 4 stimulation, not by TLR9 or TLR3-
dependent mechanisms (147). Subsequent studies have shown that the administration 
of recombinant human IL-1R antagonists may also ameliorate APAP-induced liver 
injury (148). The mice lacking TLR9, Nalp3, Caspase-1 or ASC and the 
pharmacological antagonism of TLR9 alleviated APAP-induced liver injury and 
increased survival 72 h after administration (145). 
In view of all above information, it is obvious that a large amount of DAMP is 
released after APAP-induced necrosis, and excessive DAMPs lead to characteristic 
neutrophil and monocyte recruitment (142, 149-151) and affect signaling 
mechanisms in the cells (152) after APAP overdose. In addition, the expression of 
precursor of IL-1β gene increases, which indicates that the release of DAMP after 
APAP challenge can activate the inflammasome and change plasma IL-1β which can 
be routinely detected when APAP overdose (146). In this way, the idea that the sterile 
inflammatory response involving the activation of inflammasomes potentially 
contributes to liver damage caused by APAP in mice, which is clearly supported by 
many convincing evidences. 
 





























In this study, we aimed to:  
1) Correlate APAP hepatotoxicity with activation of UPR and markers of ER 
stress in vitro; 
2) Correlate APAP hepatotoxicity with activation of UPR and markers of ER 
stress in vivo; 
3) To understand the role of hepatocytic Xbp1 in APAP-mediated 
hepatotoxicity; 
4) To analyze the molecular mechanisms in Xbp1Δhepa mice with APAP 
challenge, in order to evaluate its potential pathophysiological relevance and 














































Reagent Manufacturer Catalog 
4X Laemmli buffer Bio-Rad, Hercules, USA 16107474 
Acetaminophen Sigma-Aldrich, Steinheim, 
Germany 
A7085 





Acetone AppliChem, Darmstadt, 
Germany 
131007 
30% Acrylamide/Bis Solution Bio-Rad, China 1610156 
AEBSF hydrochloride Thermo Fisher Scientific, 
Karlsruhe, Germany 
10563165 
Agarose electrophoresis grade Sigma-Aldrich, Steinheim, 
Germany 
A9539 
Ammonium persulfate (APS) Bio-Rad, Shinagawa, Japan 1610700 
Bovine Serum Albumin (BSA, 




Calcium chloride Sigma-Aldrich, Steinheim, 
Germany 
C5670 
Cell counting Kit – 8 Sigma-Aldrich, Steinheim, 
Germany 
96992 
Cell incubator clean reagent AppliChem, Barcelona, Spain A5230,1000 
Chloroform AppliChem, Barcelona, Spain A3691.1000 
Complete mini Roche, Mannheim, Germany 11836153001 





ImmPACT DAB HRP Substrate Vector Laboratories, 
Burlingame, USA 
SK-4105 
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D (+)-Sucrose AppliChem, Barcelona, Spain 131621.1211 
DEPC water (Water for 
molecular biology) 
AppliChem, Barcelona, Spain A7398.0500 
DMEM with high glucose, 
without L-glutamine, with 
sodium pyruvate 
GE Healthcare, Logan, USA SH30285.01 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Saint-Quentin-
Fallavier, France 
D4540 
Dithiothreitol (DTT) Thermo Fisher Scientific, 
Rockford, USA 
20291 
DNA Ladder (50 bp) Invitrogen, Vilnius, Lithuania 10416014 
di-Sodium hydrogen phosphate 
7-hydrate for analysis 
AppliChem, Barcelona, Spain 132656.1211 
ECL prime western blotting 
detection reagents   
GE Healthcare, Amersham, UK RPN2232 
Eosin Y Sigma-Aldrich, Steinheim, 
Germany 
E4009 
Ethanol absolute for analysis AppliChem, Barcelona, Spain 131086.1214 
Ethylenediamine-tetraacetic acid 




Fetal bovine serum (FBS) Thermo Fisher Scientific, 
Boston, USA 
10270106 
Formaldehyde stabilized with 
methanol for clinical diagnosis 
AppliChem, Barcelona, Spain 252931.1214 





Glutaraldehyde Electron Microscopy Sciences, 
Hatfield, USA 
16400 
Glycine for molecular biology AppliChem, Barcelona, Spain A1067,5000 
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Grégoire, France  
ADD720 









HepaRG maintenance and 





HyClone L glutamine GE healthcare life sciences, 
Logan, USA 
SH30034.01 
Trypsin EDTA Lonza, Verviers, Belgium BE17-161E 
Mayer’s hematoxylin AppliChem, Barcelona, Spain 254766.1611 
37 % Hydrochloric acid 
technical grade 
AppliChem, Barcelona, Spain  211020.1611 
30 % Hydrogen peroxide AppliChem, Barcelona, Spain 121076.1211 
Isopropanol AppliChem, Barcelona, Spain 131090.1612 
Isoflutek Karizoo, Barcelona, Spain 586259.0 
Magnesium chloride hexahydrate Sigma-Aldrich, Steinheim, 
Germany 
M2670 
Midori green advance Nippon genetics, Düren, 
Germany 
MG04 
Methanol BioChemica AppliChem, Barcelona, Spain A3493.5000 
Nonfat dried milk powder AppliChem, Barcelona, Spain A0830,0500 
Nonidet P-40 AppliChem, Barcelona, Spain A1694,0250 
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Oil Red O Sigma-Aldrich, Steinheim, 
Germany 
O0625-25G 
Osmium tetroxide Electron Microscopy Sciences, 
Hatfield, USA 
19172 
PhosSTOP Roche, Mannheim, Germany 4906837001 
Ponceau S solution Sigma-Aldrich, Steinheim, 
Germany 
P7170 
Potassium chloride> 99.0% KCl Sigma-Aldrich, Steinheim, 
Germany 
P9541-500G 
Protein assay dye reagent 
concentrate 
Bio-Rad, Hercules, USA 5000006 
Roti-histokit Carl Roth, Karlsruhe, Germany 6638.2 
Restore western blot stripping 
buffer 500ml 
Thermo Fisher Scientific, 
Rockford, USA 
21059 
Sodium chloride for molecular 
biology 
AppliChem, Barcelona, Spain A2942,5000 
Sodium dhydrogen phosphate 
momohydrate 
AppliChem, Barcelona, Spain 106346,1000 
Sodium fluoride Sigma-Aldrich, Steinheim, 
Germany 
215309 
Sodium dodecyl sulfate (SDS) AppliChem, Barcelona, Spain A2572,0500 
Sodium hydroxide  AppliChem, Barcelona, Spain 131687 
STF-083010 Medchemexpress, New Jersey, 
USA 
307543-71-1 
TEMED Bio-Rad, Hercules, USA 1610801 
Tissue-Tek® O.C.T.™ 
Compound 
Sakura, Warsaw, Poland 4583 
Trizol reagent  Thermo Fisher Scientific, 
Austin, USA 
5596018 
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Tris AppliChem, Barcelona, Spain A1379,1000 
tri-Sodium citrate 2-hydrate AppliChem, Barcelona, Spain 1316551210 
Triton X-100 AppliChem, Barcelona, Spain A4975,0100 
Tween 20 Sigma-Aldrich, Saint-Quentin-
Fallavier, France 
P1379-500ML 
William’s E medium, 
GlutaMAX™ Supplement  
Gibco, Paisley, UK 3255108 
Xylene Carl Roth, Karlsruhe, Germany 9713.5 
 
5.1.2 Standard buffer and media 
10x SDS-Running Buffer Volume/Quality 
Tris 30.3 g 
Glycine 144.13 g 
SDS 10 g 
dH2O add to 1 L 
 
10x Transfer Buffer Volume/Quality 
Tris 30.3 g 
Glycine 144.13 g 
dH2O add to 1 L 
1x Transfer Buffer Volume/Quality 
10x Transfer Buffer 100 ml 
Methanol 200 ml 
dH2O add to 1 L 
 
10x TBS Volume/Quality PH value 
Tris 24.2 g PH=7.6 
NaCl 80 g 
dH2O add to 1 L 
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1x TBST Volume/Quality  
10x TBS 100 ml  
Tween-20 0.5 ml  
dH2O add to 1 L  
 
10x PBS Volume/Quality 
NaCl 78.8 g 
KCl 3.5 g 
Na2HPO4 26.8 g 
NaH2PO4 2.76 g 
dH2O add to 1 L 
 
NP40 Buffer Volume Final concentration 
Tris/HCl 7.5 pH (1 M) 25 ml 50 mM 
NaCl (5 M) 15 ml 150 mM 
Nonidet P-40 2.5 ml 0.5 % 
Sodium Fluoride 1.05 g 50 mM 
dH2O added to 500 ml  
 
5.1.3 Standard kits and enzymes 
Kit / Assay  Manufacturer  
NID buffer Volume/Quality Final Concentration PH value 
KCl 3.73 g 0.05 M PH=8.3 
Tris 10 ml 0.01 M 
MgCl2 0.41 g 2 mM 
Gelatine Type B 0.1 g 0.1 mg/ml 
NP-40 4.5 ml 0.45 % 
Tween-20 4.5 ml 0.45 % 
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In Situ Cell Death Detection Kit, 
Fluorescein  
Roche, Mannheim, Germany  
High Capacity cDNA Reverse 
Transcription Kit 
Thermo Fisher Scientific, Vilnius, 
Lithuania 
Cell Counting Kit - 8 Sigma-Aldrich, Darmstadt, Germany 
Triglycerides liquicolor mono kit RAL, Barcelona, Spain 
ImmPACTI DAB HRP Substrate Vector Laboratories, Burlingame, USA 
 
Enzyme  Manufacturer  
Proteinase K-Solution  AppliChem, Darmstadt, Germany  
ReadyMixTM redtaqTM PCR reaction 
mix with MgCl2  
Sigma-Aldrich, Steinheim, Germany  
RNAse Sigma-Aldrich, Steinheim, Germany  
SYBR® GreenERTM qPCR Super Mix  Invitrogen, Karlsruhe, Germany  
 
5.1.4 Antibodies used for immunostaining and/or western blot 
5.1.4.1 Primer antibodies 
Product Manufacturer Catalog Concentration 
pAKT Cell Signaling 
Technology 
9271S 1:1000 (WB) 
AKT Cell Signaling 
Technology 
9272S 1:1000 (WB) 
p-AMPKα (T172) Cell Signaling 
Technology 
2535S 1:1000 (WB) 
AMPKα Cell Signaling 
Technology 
2532S 1:1000 (WB) 
BIP Cell Signaling 
Technology 
3177S 1:1000 (WB) 
Cytochrome P450 Abcam ab28146 1:1000 (WB) 




CD11b BD Bioscience 550282 (M1/70) 1:100 (IF) 
CD45 BD Bioscience 550539 (30-
F11) 
1:100 (IF) 
CHOP Cell Signaling 
Technology 
2895S 1:1000 (WB) 
Cleaved Caspase3 Cell Signaling 
Technology 
9661S 1:1000 (WB) 
F4/80 BIO-RAD MCA497 
 
1:100 (IF) 
GAPDH BIO-RAD MCA4739 1:5000 (WB) 
4HNE Abcam ab46545 1:100 (IHC) 
p-IRE1α NOVUS 
BIOLOGICALS 
NB100-2323 1:1000 (WB) 
IRE1α Cell Signaling 
Technology 
3294S 1:1000 (WB) 
IL-1β Abcam ab9722 1:1000 (WB) 
Ki67 Abcam ab16667 1:100 (IHC/IF) 
pJNK Cell Signaling 
Technology 
9251S 1:1000 (WB) 
JNK Cell Signaling 
Technology 
9252S 1:1000 (WB) 
pJNK1 BIONOVA (Novus 
Biologicals) 
NB100-82009 1:1000 (WB) 
JNK1 Cell Signaling 
Technology 
3708S 1:1000 (WB) 
pJNK2 BIONOVA (Novus 
Biologicals) 
NBP1-45787 1:1000 (WB) 
JNK2 Cell Signaling 4572S 1:1000 (WB) 




LC3A/B (D3U4C) Cell Signaling 
Technology 
12741 1:1000 (WB) 
NLRP3 Abcam ab214185 1:1000 (IHC) 
P62 Cell Signaling 
Technology 
39749 1:1000 (WB) 





XBP1 Abcam ab37152 1:1000 (WB) 
ZO-1 Invitrogen 61-7300 1:1000 (WB) 
XBP1 Abcam ab220783 1:1000 (WB) 
 
5.1.4.2 Secondary antibodies 
Product Manufacturer Catalog Concentration 
Anti-rabbit-HRP Cell Signaling 
Technology 
7074S 1:3000 (WB) 
Anti-Mouse-HRP BIO-RAD STAR207P 1:5000 (WB) 
Anti-Rabbit-HRP 
IgG 








Invitrogen A-11006 1:400 (IF) 
Goat-Anti-Mouse 
(IF, 488) 
Invitrogen A-11001 1:400 (IF) 
Donkey-Anti-
Rabbit (IF, 488) 
Invitrogen A-21206 1:500 (IF) 
5.1.5 Primer sequences used for RT-qPCR 
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5.1.5.1 Primer for Human: 

















5.1.5.2 Primer for Mouse: 
Gene Forward Reverse 
Atg5 ACAGCTTCTGGATGAAAGGC TGGGACTGCAGAATGACAG
A 
Beclin1 TGA TCC AGG AGC TGG AAG 
AT 
CAA GCG ACC CAG TCT 
GAA AT 
Bip TTC AGC CAA TTA TCA GCA 
AAC TC 
TTT TCT GAT GTA TCC TCT 
TCA CC 
Casp1 TCC CAG TCA GTC CTG GAA 
ATG 
ACA AGG CAC GGG ACC 
TAT G 
Chop CCA CCA CAC CTG AAA GCA 
GAA 
AGG TGA AAG GCA GGG 
ACT CA 
Cye2e1 CGCTTCGATTACGATGACAA TGTGCTGGTGGTCTCTGTTC 
eIF2α GGA CCA CCA CAC TTC ACA 
GA 
TCC CTT GTT AGC GAC ATT 
GA 









IL-1β TGT GTG ACG TTC CCA TT CAG CAC GAG GCT TTT 
TTG TTG 
Ire1α TGC TCA AGG ACA TGG CTA 
CCA TTA 
CTG GAA CTG TTG GTG 
CTG GA 
Lc3b CCG AGA AGA CCT TCA AGC 
AG 
ACA CTT CGG AGA TGG 
GAG TG 
Nlrp3 TGT GAG AAG CAG GTT CTA 
CTC T 
TGT AGC GAC TGT TGA 
GGT CCA 
p62 AGA ATG TGG GGG AGA GTG 
TG 









5.1.6 Primer sequences used for genotyping PCR 





AlbCre-01 TGC AAA CAT CAC ATG CAC AC 
AlbCre-02 TTG GCC CCT TAC CAT AAC TG 
AlbCre-03 GAA GCA GAA GCT TAG GAA GATGG 
 
Materials and Methods 
47 
 
5.1.7 Instruments and equipment 
Product Manufacturer 
Adobe Photoshop CS6 13.0*32 Adobe Systems, San Jose, USA 
AxioVision SE64. Rel.4.9 Carl Zeiss Microscopy GmbH, München, 
Germany 
Centrifuge 5415 D Eppendorf AG, Hamburg, Germany 
Centrifuge 5804/5804R Eppendorf AG, Hamburg, Germany 
Centrifuge 5920 R Eppendorf AG, Hamburg, Germany 
Centrifuge 4K15 10740 DJB Labcare Ltd, Buckinghamshire, UK 
Centrifuge Z233M-2 and Refrigerated 
Z233MK-2 
Hermle Labor Technik GmbH, Wehingen 
Germany 
Class II Bio II Advance Plus 
Microbiological Safety Cabinet 
Azbil Telstar Technologies Slu, 
Barcelona, Spain 
Cryostat CM1950 Leica Biosystems Nussloch GmbH, 
Wetzlar, Germany 
Digital microscope camera Moticam 
2500 
Ryf AG, Bettlachstrasse, Switzerland 
Gel Doc 2000 System BioRad, Neuberg, Germany 
ImageJ Version 1.52u LOCI, University of Wisconsin, USA 
Leica EG1160 Embedding Center, 
Dispenser + hot Plate 
Leica Biosystems Nussloch GmbH, 
Wetzlar, Germany 
Leica MZ16 Stereomicroscope with 
Leica DFC480 Digital Camera 
Leica Microsystems, Milton Keynes, 
United Kingdom 
Leica HI1210 Water bath for paraffin 
sections 
Leica Biosysetems, Heidelberger, 
Germany 
Leica RM2125 RTS - The Essential 
Microtome 
Leica Biosysetems, Heidelberger, 
Germany 
Microcentrifuge National Labnet, Madrid, Spain 




5.1.8 Other equipment 
Plastic and Glassware Manufacturer Catalog 
Big flacon 50ml Labbox, Barcelona, Spain PTGP-E050-500 
Blue tips 1ml 
Greiner Bio-One,  
Frickenhausen, Germany  
740290 
Cell culture plate sterile, 96 Well, 
F-bottom with lid 
Greiner Bio-One,  
Frickenhausen, Germany  
655180 
CellStar® Cell Culture Multiwell 
Plates, Wells=6 
Greiner Bio-One,  
Frickenhausen, Germany 
657160 
CELLSTAR® Cell Culture Greiner Bio-One,  665180 
7300 Real Time PCR System AND 
Sequence Detection Software Version 
1.3.1 
Applied Biosystems, Darmstadt, 
Germany 
2100-Retriever Aptum Biologics, Hants, United 
Kingdom 
Odyssey Fc Imaging system LI-COR, Madrid, Spain 
Transmission electron microscope 
(TEM) Jeol 1010 
Jeol, Peabody, USA 
Thermo Scientific Forma Steri-Cycle 
i250 C02 incubator 
Thermo Fisher Scientific, Boston, USA 
Thermomixer Eppendorf, Hamburg, Germany 
Vertical laminar flow workbench, Mini- 
V/PCR 
Azbil Telstar Technologies Slu, 
Barcelona, Spain 
Vortex Reax 200 Heildophin, Nürnberg, Germany  
Video Copy Processor P90E Mitsubishi, Kyoto, Japan 
Water bath (STANDARD of 12877) DILABO, Torralba de Calatrava, Spain 
ZEISS Axio Lab.A1 Carl Zeiss Microscopy GmbH, Jena, 
Germany 
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Multiwell Plates, Wells=12 Frickenhausen, Germany 







Thermo Fisher Scientific, 
Suzhou, China 
375353PK 




Eppendorf® Reference® 2 G 





Eppendorf® Reference® 2 G 
single-channel, fixed, volume (100 
μl) 
Eppendorf, Hamburg, 
Germany  EP4925000103 
Eppendorf® Reference® 2 G 




Eppendorf™ Tubes (1.5ml) 
Thermo Fisher Scientific, 
Hamburg, Germany 
10398031 
Falcon Tissue Culture Treated 
Flasks (50ml) 
Thermo Fisher Scientific, 
Hamburg, Germany 
10634501 
Falcon Tissue Culture Treated 
Flasks (250ml) 
Thermo Fisher Scientific, 
Hamburg, Germany 
10537161 




MicroAmp Fast Optical 96 Well 
Reaction Plate, 0.1ml 
Thermo Fisher Scientific, 
Suzhou, China 
43-469-06 
MicroAmp Optical Adhesive Film Thermo Fisher Scientific, 43-119-71 




MicroAmp Optical 8-Tube Strip 
with attached optical caps 
Thermo Fisher Scientific, 
Cramlington, UK 
A30588 
Mini Trans-Blot® Electrophoretic 
Transfer Cell 
Bio-Rad, Portland, USA 170-3930 
Nitrocellulose blotting membrane, 




Nitrocellulose blotting membrane, 




Pipettes 5 ml 
Greiner Bio-One,  
Frickenhausen, Germany  
606107 
Pipettes 10ml 
Greiner Bio-One,  
Frickenhausen, Germany  
607180 
Polyvinylidene difluoride (PVDF) 
membrane 
Bio-Rad, Hercules, USA 1620264 
Sarstedt Inc PC MTUBE 1.1ML 
SER-GEL/PK100 
Thermo Fisher Scientific 
Suzhou, China 
NC9436363 
Slides Klinipath, Lutterworth, UK PR-S-100 
Syringes 1 mL Luer  
BD Plastipak, Madrid, 
Spain 
303172 
Small falcon 15ml Labbox, Barcelona, Spain PTGP-E15-500 
Syringe 1 ml with 27 × 13 needle 
BD Plastipak, Madrid, 
Spain 
300635 
Whatman® paper (Thick Blot Filter 
Paper, For WB) 
BIO-RAD, Hercules, USA 1704085 
Yellow tips 200μl 
Greiner Bio-One,  




5.2.1 Housing and breeding of mice 
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All mice strains were housed in filter-top cages and bred in a pathogen-free, 
temperature and humidity-controlled facility at the Institute for Medicine faculty, 
Complutense University (UCM). The animal facility was standardized with 12 h light-
dark cycles and the mice had free access to standard food and water. All animal 
experiments were approved by the authorities and all animal received humane care 
according to laws on protection of animals and University requirements and guidelines 
(PROEX- 218/17).  
5.2.2 Mice strain 
For our study we used WT male mice with C57BL/6 background (ENVIGO, 
Valencia, Spain), and mice of male gender with specific hepatic-knockout of Xbp1 
(Xbp1∆hepa) and Xbp1 floxed (Xbp1f/f) littermates from same breeding couples with 
C57BL/6 background. C57BL/6-Xbp1f/f mice with loxP sites flanking exon 2 of the 
Xbp1 gene were kindly provided by prof. Eduardo Martinez Naves (153), and 
C57BL/6-Albumin-Cre mice were purchased from The Jackson Laboratory (B6.Cg-
Tg(Alb-cre)21Mgn/J, Maine, USA). Alb Cre mice were crossed to Xbp1f/f mice to 
generate Xbp1∆hepa mice. These mice allowed to analyze XBP1 function selectively in 
hepatocytes in vivo. 
5.2.3 Genotyping of genetically modified mice 
The correct genotypes were verified by PCR analysis. DNA was prepared from 
fresh mouse tail biopsies using NID buffer. Each tail was digested with 200 μl of NID 
buffer and 1 μl of proteinase K (AppliChem, Darmstadt, Germany) at 56°C overnight. 
Enzyme activity was stopped by heating at 95°C for 10 min. Then the tails were 
centrifuged at 12000 rpm for 10 min, and 2 μl of the supernatant was used for PCR 
reaction. 
NID buffer was prepared as follows: 
Reagent Volume/Quality Final Concentration PH value 
KCl 3.73 g 0.05 M PH=8.3 
Tris 10 ml 0.01 M 
MgCl2 0.41 g 2 mM 
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PCR reaction reagents were as follows: 
a. Mixture for genotyping for Xbp1: 
Reagent Volume 
DNA 2 μl 
Primer 01 1 μl 
Primer 02 1 μl 
RedTaq 12.5 μl 
DEPC H2O 8.5 μl 
TOTAL 25 μl 
b. Mixture for genotyping for AlbCre: 
Reagent Volume 
DNA 2 μl 
Primer 01 1 μl 
Primer 02 1 μl 
Primer 03 1 μl 
RedTaq 12.5 μl 
DEPC H2O 7.5 μl 
TOTAL 25 μl 
PCR was carried out according to the following cycling programs: 
a. Program for genotyping for Xbp1: 
PCR program  temperature  time (h:min:sec)  Cycles  











final elongation  72°C  00:10:00   
Gelatine Type B 0.1 g 0.1 mg/ml 
NP-40 4.5 ml 0.45 % 
Tween-20 4.5 ml 0.45 % 
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conservation  4°C  00:00:00  
b. Program for genotyping for Albcre: 
PCR program  temperature  time (h:min:sec)  Cycles  




























PCR products were separated by 2% (w/v) agarose gels. The agarose was boiled 
in 1x TAE buffer until the solution is completely clear and no small floating particles 
are visible, cooled at room temperature for 5-10 min, and 6 μl of MIDORI Green 
Advance (Nippon genetics, Düren, Germany) was added and mixed gently. Gel were 
run in 1x TAE buffer at 120 V. DNA ladders (Invitrogen, Vilnius, Lithuania) were used 
to determine the specific size of fragments. After the electrophoretic run, view the 
results on a UV-transilluminator and print out with Video copy processor. 
5.2.4 Blood and tissue sampling procedures 
5.2.4.1 Taking of blood samples 
8-12 weeks old mice were sacrificed under overdose by isoflurane, following the 
abdominal cavity was cut open along the linea alba. Intestine was moved aside to 
expose the inferior vena cava. Blood samples were extracted out by penetrating the 
inferior vena cava with a 1 ml syringe and then were collected in a serum tube and 
centrifuged at 12000 rpm for 10 min. Serum transaminases are specific markers for 
liver damage. For this study, serum was diluted 1:5 for measuring serologic markers 
such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate 
dehydrogenase (LDH) in the clinical laboratories of hospital Gregorio Maranon, 
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Madrid. The left serum was stored at -80°C. 
5.2.4.2 Extraction and sectioning of liver 
At the mice were sacrificed, their body weight was recorded. The liver was 
carefully taken out and the liver weight was recorded. Then the liver was cut into small 
pieces in the same way for RNA isolation and protein isolation stored in liquid nitrogen 
and then transferred to -80°C. And two pieces from different livers were fixed in 4% 
formaldehyde for 48 h and then embedded in paraffin. Using paraffin blocks, serial 5 
μm sections were performed and subsequently stained with H&E or 
immunohistochemical staining following routine protocols. The same part of each liver 
was taken and put the fresh liver tissue in Tissue-Tek® O.C.T.™ Compound (Sakura, 
Warsaw, Poland) and kept in -80°C for the frozen section.  
5.2.5 Intraperitoneal injection of APAP and STF-083010 
10-12 weeks old WT mice got an intraperitoneal (IP) injection of acetaminophen 
(0-300 mg/kg). Before injection, mice were fasted overnight. Mice were gently 
restrained by grasping the mice by the loose skin of the neck and back to immobilize 
the head. Identify anatomical landmarks in order to inject into the appropriate area of 
the abdomen, usually the lower right quadrant of the mice abdomen. Disinfect the skin, 
insert needle with bevel facing “up” towards the head at 30‐40ᵒ angle to horizontal, and 
then inject acetaminophen (Sigma-Aldrich, Steinheim, Germany). Xbp1∆hepa and Xbp1f/f 
littermates were challenged with an intraperitoneal (IP) injection of acetaminophen 
(500 mg/kg) or vehicle. Because the dose is high and acetaminophen is insoluble in 
water, acetaminophen should be dissolved in DMSO first, then dilute to 50 mg/ml 
acetaminophen solution in warm PBS. Control mice received an equivalent volume of 
PBS with DMSO. The concentration of DMSO should be less than 1%. Then the mice 
were kept fasted for another 2 h, and allowed food ad libitum. 
We also applied STF-083010 (MedchemExpress, New Jersey, USA) in WT mice 
to further explore the role of Xbp1 in APAP-induced liver injury. STF-083010 is a small 
molecule inhibitor of Xbp1 splicing by directly inhibiting IRE1α RNase activity, as the 
potent treatment modality for ER stress-induced impairments. Similar to APAP, STF-
083010 was first dissolved in 10% DMSO then diluted in room temperature PBS. 75 
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mg/kg STF-083010 or equal volume of PBS with 10% DMSO were intraperitoneally 
injected 1 h before APAP model induction based on the study of Chen Shen et al (154).  
5.2.6 Cell culture  
5.2.6.1 Cell culture procedures 
HepaRGTM cells (Biopredic international, Saint-Grégoire, France) is a unique and 
well-established hepatic cell system, which can produce not only early hepatic 
progenitor cells but also mature human hepatocytes. HepaRG cells provide an in vitro 
tool to do research in a fully metabolic and scalable system. HepaRG cells were 
purchased from Biopredic (Saint Gregoire, France).  
HepaRG cells is cultured using specialized media at 37°C, 5% CO2 and saturating 
humidified atmosphere following the supplier’s protocols. Each medium was made up 
using William’s Medium E with 1% GlutaMAX (Gibco, Paisley, UK) as the basal 
medium with appropriate additives. Number was determined using counting chamber 
and trypan blue staining. Viability of cells was measured by cell counting kit-8 (CCK-
8) (Sigma-Aldrich, Darmstadt, Germany). Cells were first maintained in growth 
medium for 2 weeks, then changed to differentiation medium for another 2 weeks. At 
this stage, HepaRG cells reach a differentiated hepatocyte-like morphology and express 
liver-specific functions. Then differentiated cells were plated on 6-well tissue culture 
plate (protein and RNA extraction), 96-well cell culture plate (quantitation of cell 
viability) or 12-well tissue culture plate with coverslips (immunofluorescence) with 
thaw, plate & general purpose working medium, 2 days later changed to 
maintenance/metabolism medium. 7 days after plating, the cells are ready for 
experiments. Differentiated HepaRG cells were fasted 4 h and challenged with different 
concentrations of acetaminophen (0-20 mM). 24 h after APAP challenge, HepaRG cells 
and supernatant were collected. The coverslips were fixed with 4% PFA for 14 min, 
then stored in PBS at 4°C for TUNEL, ORO and ZO-1 staining.  
5.2.7 Isolation and analysis of RNA 
5.2.7.1 RNA isolation and determination of RNA concentration 
RNA was extracted from frozen mouse liver using TRIZOL (Thermo Fisher 
Scientific, Austin, USA) according to the manufacturer’s recommendations. A little 
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piece of liver tissue was minced in TRIZOL with an electric homogenizer. After adding 
200 μl chloroform, the lysates were incubated at room temperature for at least 20 min 
followed by centrifugation at 12000 rpm at 4℃. The upper supernatant was incubated 
15 min with isopropanol and RNA was pelleted by centrifugation at 12000 rpm at 4℃. 
The supernatant was discarded and the pellets were washed twice with 1 ml 70% 
ethanol, then dried at room temperature. According to the size of the pellets, appropriate 
volume of DEPC water was added and the pellets were resuspended. RNA 
concentration of each sample was measured using spectrophotometry at an optical 
density (OD) of 260 nm. dH2O was used as blank. Purity of the sample was determined 
by the ratio of E260/ E280. RNA was stored at -80°C. 
5.2.7.2 Reverse transcription (RT) 
Reverse transcription is a process to transcribe single-stranded RNA to 
complementary DNA (cDNA). According to the results of concentration measurement, 
each RNA sample was standardized into a dilution with a concentration of 1 μg/μl. 
Reverse transcription was performed with Applied Biosystems™ High-Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher Scientific, Vilnius, Lithuania) following the 
manufacturer’s instructions. The reaction system is prepared in 20 μl volume. The 
components and the ratio are as follows: 
Reagents Volume 
RNA sample Total 10 μl 
DEPC WATER 
DEPC WATER 4.2 μl 
10x buffer RT 2 μl 
25x dNTPs 0.8 μl 
10X random PRIMER 2 μl 
Enzyme Reversetranscriptase 1 μl 
Total volume 20 μl 
Reactions were incubated in a PCR thermocycler at 25°C for 10 min, followed by 
at 37°C for 120 min, at 85°C for 5 min and then cooled to 4°C. After reverse 
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transcriptase, the cDNA was diluted 1:5 with purified water and stored at -20°C. 
5.2.7.3 Real-time PCR 
Quantitative real-time PCR is a method that uses fluorescent chemicals to measure 
the total amount of products after each polymerase chain reaction (PCR) cycle in a 
DNA amplification reaction. qPCR was performed in 20 μl reaction volume using 
SYBR Green Master Mix (Invitrogen, Karlsruhe, Germany) and a 7300 real time PCR 
system. At the end of the PCR, baselines and threshold values were established using 
AB 7300 System SDS software, and the CT values were exported to Microsoft Excel 
to calculate relative mRNA expressions according to the ΔΔCT method (155). The CT 
value of each sample was compared with the control group and normalized against 
Gapdh gene expression as an internal reference. The compositions of real-time PCR in 
this study were as followed: 
Reagents  Volume 
cDNA 5 μl 
Forward primer 1 μl 
Reverse primer 1 μl 
SYBR green master mix 10 μl 
DEPC water 3 μl 
Total reaction volume 20 μl 
5.2.8 Protein extraction and analysis 
5.2.8.1 Isolation of whole cell protein from the liver 
Appropriate size of the frozen liver tissue (approximately 1 mg) was homogenized 
on ice with 500 μl NP40 lysis buffer. The composition of NP40 buffer was as follow: 
NP40-Buffer Volume Final concentration 
Tris/HCl 7.5 pH (1 M) 25 ml 50 mM 
NaCl (5 M) 15 ml 150 mM 
Nonidet P-40 2.5 ml 0.5 % 
Sodium Fluoride 1.05 g 50 mM 
dH2O added to 500 ml  
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Reagents shown as follow need to be added fresh before use: 
Freshly added components Volume 
PhosSTOP 1 tablet 
Complete Mini (protease inhibitors) 1 tablet 
DTT (1 M) 20 μl 
AEBSF Hydrochloride (100 mM) 100 μl 
NP40 buffer added to 10 ml 
The homogenate was incubated on ice for at least 1 h, then centrifuged for 10 min 
at 12000 rpm and 4°C. The supernatant was transferred into a fresh tube. 
5.2.8.2 Protein quantification 
Protein concentrations from liver tissue were measured according to Bradford 
method using BIO-RAD Protein Assay reagent (156). BSA was diluted to 0.5 mg/ml, 
1 mg/ml, 2 mg/ml, 4 mg/ml, 6 mg/ml, 8 mg/ml, 10 mg/ml in NP40 buffer for generating 
the standard curve. NP40 buffer was used as blank control. 2 μl of each protein sample 
or BSA standard was mixed with 998 μl Bio-Rad protein reagent (Bio-Rad, Hercules, 
USA), which had been diluted in MilliQ water with the final concentration of 20%. 200 
μl mixed solution was added into 96-well plate and measured using a 
spectrophotometer at OD630. Protein concentrations were calculated according to the 
standard curve drawn from the OD630 values of BSA standard proteins. The final 
concentration of proteins was diluted to 4 μg/μl with NP40 lysis buffer and stored at -
80°C. 
5.2.8.3 Western blot 
Handmade gels and buffers were prepared ahead. The concentrations of separating 
gel depend on the molecular weight of target proteins. The compositions of gels and 
buffers were as follows: 
Separating Gel 8 % 10 % 12 % 15 % 




5.3 6.7 8.0 10.0 





5.0 5.0 5.0 5.0 
SDS 10% (ml) 0.2 0.2 0.2 0.2 
APS 10 % (ml) 0.2 0.2 0.2 0.2 
TEMED (ml) 0.012 0.008 0.008 0.008 
Total volume (ml) 20 20 20 20 
 
Stacking Gel Volume 
dH2O  4.5 ml 
30% Acrylamide/Bis Solution  1.3 ml 
Tris/HCL PH=6.8  2 ml 
SDS 10%  0.08 ml 
APS 10 %  0.08 ml 
TEMED  0.008 ml 
Total volume  8 ml 
The molecular weights of proteins separated by different concentrations of separation 
gel are as follows (4): 
 
The buffers used in WB are as follow: 
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10x SDS-Running Buffer Volume/Quality 
Tris 30.3 g 
Glycine 144.13 g 
SDS 10 g 
dH2O add to 1 L 
 
10x Transfer Buffer Volume/Quality 
Tris 30.3 g 
Glycine 144.13 g 
dH2O add to 1 L 
1x Transfer Buffer Volume/Quality 
10x Transfer Buffer 100 ml 
Methanol 200 ml 
dH2O add to 1 L 
 
10x TBS Volume/Quality PH value 
Tris 24.2 g PH=7.6 
NaCl 80 g 
dH2O add to 1 L 
1x TBST Volume/Quality  
10x TBS 100 ml  
Tween-20 0.5 ml  
dH2O add to 1 L  
1/4 volume of loading buffer was added into protein samples and the mixtures 
were denatured for 5 min 300 rpm at 95°C in the thermomixer. 80-100 μg proteins were 
loaded on a handmade gel and separated at 80-120 V for approximately 2 h in 1x SDS-
Running buffer. After electrophoresis, the separated proteins were transferred from the 
gel onto a PVDF membrane or a Nitrocellulose membrane in the wet blotting chamber 
for 2 h at 300 mA on ice. Whatman® paper, membrane and gel were made like the 
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sandwich then immersed in 1x transfer buffer. The transfer was carried out in 
accordance with standard procedures (157) and the transfer sequence is critical and 
need to be placed correctly. The successful transfer was confirmed by Ponceau S Red 
staining. The membrane was cutting according to the molecular weight of target 
proteins, and incubated in 5% BSA/0.5% TBS-Tween 20 (TBST) or 5% non-fat 
milk/0.5% TBST for 1 h at room temperature to block non-specific binding sites. After 
blocking, the membranes were incubated with primary antibody diluted in 2.5% 
BSA/0.5% TBST or 2.5% non-fat milk/0.5% TBST overnight at 4°C on a shaker. On 
the second day, the membranes were washed three times in TBST for 10 min, then 
incubated with the horseradish peroxidase (HRP)-conjugated secondary antibody in 5% 
BSA/0.5% TBST or 5% non-fat milk/0.5% TBST at room temperature. One hour later, 
secondary antibody was taken away and the membranes were washed three times in 
TBST for 10 min again. Target bands were visualized using Amersham enhanced 
chemiluminescence (ECL) Prime (GE Healthcare, Amersham, UK). After incubation 
for 2 min, the membrane was exposed to an odyssey Fc Imaging system (LI-COR, 
Madrid, Spain) until specific signals were detectable.  
5.2.9 Histological analysis 
5.2.9.1 Immunofluorescence (IF) staining 
Five µM cryosections from mouse liver were air dried for 20 min, then fixed in 4% 
formaldehyde at room temperature, followed by washing with PBS three times for 5 
min. A humid box was made to prevent the slides from dying and fading. PBS 
containing 5% goat serum and 0.3% Triton was used for blocking followed by 
incubation with primary antibody in blocking solution at optimized dilutions at 4°C 
overnight. On the second day, slides were washed with PBS three times for 10 min and 
incubated with secondary antibody labeled with Alexa fluorescent dye in blocking 
solution for 1 h at room temperature. Then slides were washed three times for 10 min 
in PBS. Nuclei were counterstained with Vectashield mounting medium containing 
DAPI (Vector Laboratories, Burlingame, USA). Microscopy and image acquisition 
were performed using an Axio Imager A1 microscope and AxioVision software. 
ImageJ software was used for image analysis and quantification. 
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5.2.9.1.1 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining 
The coverslips were put in 6-well plate and incubated in 3% Hydrogen peroxide 
diluted in Methanol (30% Hydrogen peroxide : Methanol = 1:9) for 10 min in the dark, 
followed by incubated in PBS for another 10 min. 150 mM Na-Citrate solutions were 
prepared and dropped on the coverslips. 2 min later, the Na-Citrate solution was 
removed and the coverslips were washed with PBS solution for 5 min three times, 
followed by incubating with labeling mixture solution overnight at 4ºC. On the second 
day, the coverslips were washed in PBS solution three times for 10 min, then mounted 
with DAPI for nuclear counterstaining.  
Five µM cryosections from mouse liver were dried in air for 30 min, then fixed in 
4% formaldehyde at room temperature for 20 min, followed by washing with PBS three 
times for 10 min. Then slides were incubated in 3% Hydrogen peroxide diluted in 
Methanol (20 ml 30% Hydrogen peroxide + 180 ml Methanol) for 10 min in the dark, 
followed by incubated in PBS for another 10 min. To have access to the DNA, the 
nuclei were permeabilized in 150 mM Na-Citrate solution. 150 mM Na-Citrate 
solutions were prepared as follows and cooled with glass tank at advance: 
Reagent Volume/Quality PH value 
150 mM Na-Citrate 8.8 g PH=6.0 
PBS solution 200 ml 
10X Triton-100 0.2 ml 
The permeabilization solution was removed by washing twice in PBS solution for 
10 min. Then slides were incubated with labeling mixture solution overnight at 4ºC. 
The labeling mixture solution was composed as below: 
Reagent Volume for 1 section (2 samples) 
Enzyme Solution 1 µl 
10X TUNEL Diluent Buffer  10 µl 
TUNEL Labeling Solution  89 µl 
Total 100 µl 
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On the second day, the slides were washed with PBS solution four times for 10 
min, then mounted with DAPI for nuclear counterstaining. 
5.2.9.1.2 Zonula occludens-1 (ZO-1) staining 
The coverslips were put on the slides and blocked with PBS containing 10% goat 
serum, followed by incubation with ZO-1 antibody in PBS containing 1% goat serum 
at dilution of 1:100 at room temperature for 1 h. After washed with PBS three times for 
10 min, the coverslips were incubated with secondary antibody labeled with Alexa 
fluorescent dye in PBS containing 1% goat serum for 45 min at room temperature, then 
washed three times for 10 min in PBS and mounted with DAPI for nuclear 
counterstaining.  
Five µM cryosections from mouse liver were dried in air for 25 min, then fixed in 
4% formaldehyde at room temperature for 10 min, followed by washing with PBS three 
times for 10 min. PBS containing 10% goat serum was used for blocking followed by 
incubation with primary antibody in PBS containing 1% goat serum at dilution of 1:100 
at room temperature for 1 h. After washed with PBS three times for 10 min, the slides 
were incubated with secondary antibody labeled with Alexa fluorescent dye in PBS 
containing 1% goat serum for 45 min at room temperature. Then slides were washed 
three times for 10 min in PBS, then mounted with DAPI for nuclear counterstaining.  
5.2.9.2 Dihydroethidium (DHE) staining 
Fresh five µM cryosections from mouse liver were dried in air for 30 min, 
followed by washing with PBS for 5 min. Then the slides were incubated 10 µmol DHE 
at 37ºC for 15 min, then washed with PBS for 5 min. After fixed in 4% formaldehyde 
at room temperature for 5 min, the slides were mounted with DAPI for nuclear 
counterstaining. 
5.2.9.3 Immunohistochemistry (IHC) staining 
Five µM Paraffin embedded sections were baked in the oven at 60℃ for 0.5 h, 
then deparaffinized and rehydrated with xylene and serial ethanol solutions from 100% 
to 70%. Antigen unmasking was performed by boiling sections in 10 mM sodium citrate 
buffer using Antigen 2100-Retriever (Aptum Biologics, Hants, UK) for one complete 
cycle (approximately 2 h). After cooling, sections were rinsed in dH2O three times for 
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5 min and treated with 3% H2O2 for 10 min to quench endogenous peroxidases. Slides 
were washed again in dH2O twice, then washed in PBS for 5 min. Sections were 
blocked with 2.5% horse serum (Vector Laboratories, Burlingame, USA) for 20 min at 
room temperature. Removed away blocking solution, the slides were incubated with 
primary antibody diluted in PBS with 1% BSA and 0.3% Triton overnight at 4℃ in a 
humid chamber. The next day, the slides were washed with PBS three times for 5 min, 
then incubated with secondary antibody (Vector Laboratories, Burlingame, USA) at 
room temperature for 1 h in the humid chamber. After washed three times in PBS, 
signals were developed with DAB (Vector Laboratories, Burlingame, USA) and 
counterstained with hematoxylin. Dehydrating was performed in increasing 
percentages of ethanol and xylene, mounted with Roti-histokit (Carl Roth, Karlsruhe, 
Germany) and analyzed using microscope system. 
5.2.9.4 Hematoxylin and eosin (H&E) staining 
Paraffin embedded liver samples were cut 5 µm thick and made into slides, and 
deparaffinized and rehydrated following protocol as below: 2 x 10 min xylene, 2 x 5 
min 100% ethanol, 1 x 3 min 95% ethanol, 1 x 3 min 90% ethanol, 1 x 3 min 85% 
ethanol, 1 x 2 min tap water. Then the slides were immersed in hematoxylin for 20 min, 
rinsed under warm tap water for 10 min, then waxed in 1% hydrochloric acid alcohol 
for 2 sec and rinsed under warm tap water again for 15 min. The slides were incubated 
in 70% ethanol for 3 min, 85% ethanol for 3 min and 90% ethanol for 2 min respectively, 
following with eosin staining and dehydration: 1 x 2 min eosin, 1 x 3 sec 95% ethanol, 
2 x 3 min 100% ethanol, 2 x 10 min xylene. Coverslip slides using Roti-histokit. Place 
a drop of Roti-histokit on the slide using a glass rod to allow it to spread beneath the 
coverslip, covering all the tissue.  
5.2.9.5 Oil Red O (ORO) staining 
Oil Red O staining is an effective way to detect neutral triglycerides and lipids. 
Stock solution of ORO needs to be prepared ahead: 0.5 g Oil Red powder was dissolved 
completely in 100 ml isopropanol, and kept in dark. The working solution needs to be 
prepared freshly: 48 ml stock solution diluted to 80 ml with dH2O, and filtered with 
Whatmann paper for three times.  
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The coverslips were washed three times in dH2O and stained in Oil Red O working 
solution for 40 min at room temperature, then immersed in Hematoxylin for 30 sec. The 
coverslips were rinsed with tap water until the water runs clear. Mount the coverslips 
with Roti-histokit and take pictures with a microscope. 
Eight µM frozen sections of the liver were cut and air-dried for 40 min, fixed with 
4% paraformaldehyde for 25 min, and then washed three times in dH2O. The slides 
were then stained in Oil Red O working solution for 40 min at room temperature and 
rinsed again in dH2O shortly. Hematoxylin is used for counterstaining. Take pictures 
with a microscope immediately after staining. 
Oil red O stock solution Volume 
Oil red O powder 0.5 g 
Isopropanol 100 ml 
Oil Red O working solution Volume 
Oil Red O stock solution 48 ml 
dH2O 32 ml 
5.2.10 Hepatic Triglyceride (TG) content 
Homogenization buffer for hepatic triglyceride was prepared one day before the 
experiments and kept in 4℃. The composition of homogenization buffer was as 
follow: 
Homogenization buffer Volume/Quality PH value 
Tris 390 mg PH=7.5 
EDTA 110 mg 
Sucrose 21.35 g 
dH2O 250 ml 
Approximately 20 g liver tissue was cut on dry ice, and homogenized completely 
with 1 ml homogenization buffer in tissue homogenizer. The homogenate solution was 
centrifuged for 5 min at 12000 rpm and 4°C. The upper two layers were mixed gently 
and transferred into a fresh tube. Hepatic triglyceride concentrations from liver tissue 
were measured following the manual guide of Triglycerides liquicolor mono kit (RAL, 
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Barcelona, Spain). Standard solution was diluted to 50 mg/dl, 75 mg/dl, 100 mg/dl, 125 
mg/dl, 150 mg/dl, 175 mg/dl, 200 mg/dl in dH2O for generating the standard curve. 
dH2O was used as blank control. 2 μl of each sample was mixed with 200 μl kit reagent 
and added into 96-well plate. After incubated in room temperature for 45 min, the plate 
was measured using a spectrophotometer at OD450. Hepatic triglyceride concentrations 
were calculated according to the standard curve drawn from the OD450 values of 
standard solutions.  
5.2.11 Transmission electron microscopy (TEM) 
Two mm thickness of liver tissues were fixed in fix solution (4% formaldehyde 
and 2.5% glutaraldehyde in phosphate solution) for 5 h at 4°C and incubated in 
phosphate solution overnight at 4°C. The next day, samples were post-fixed with 1% 
osmium tetroxide diluted in double-distilled water for 1 h at room temperature, 
dehydrated through graded acetone (30%-50%-70%-80%-90%-95%-100%-100%), 
infiltration in resin-acetone, and embedded in resin. Ultrathin sections were cut with a 
diamond knife on an ultramicrotome. The thin sections were stained and observed using 
a transmission electron microscope Jeol 1010 (Jeol, Peabody, USA). 
Phosphate solution Volume PH value 
2.26% NaHPO4.H2O 41.5 ml PH=7.2-7.4 
2.52% NaOH 8.5 ml 
 
Fix solution Volume 
16% PFA 2.5 ml 
25% Glutaraldehyde 1 ml 
Phosphate solution 6.5 ml 
 
5.3 Statistical analysis 
Statistical analysis was performed using the software Prism v8.0 (GraphPad 
Software). Statistical significance among groups was determined by one-way analysis 
of variance between APAP-challenged groups and control group in HepaRG cells or 
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WT mice, and by two-way ANOVA adjusted for multiple comparisons between 
Xbp1Δhepa mice and Xbp1f/f mice. Data are expressed as means ± Standard Error of the 





























6.1 APAP induces cytotoxicity and cell death in HepaRG cells 
HepaRGs, a bipotent human hepatic cell line, provide an excellent in vitro model 
system for exploring mechanisms of APAP hepatotoxicity (158). Differentiated 
HepaRG cells maintain drug-metabolizing enzymes and are more useful human hepatic 
cellular models for toxicity studies (159). Differentiated HepaRG cells were treated 
with different concentrations of APAP range from 0 mM to 20 mM for 24 h. HepaRG 
cells exposed to APAP showed a dose-response reduction in cell viability at 24 h. 
Cytotoxicity assessments were done by CCK8 assay and morphological assessments by 
confocal fluorescence microscopy. CCK8 solution is stable and low in cytotoxicity, and 
can be added directly to the cells. An orange formazan product bioreduced by cellular 
dehydrogenases was proportional to the number of living cells. Cell viability decreased 
around 50% with 10 mM and only 30% HepaRGs treated with 20 mM APAP survived 
at 24 h according to CCK8 measurement (Fig. 6A). HepaRG cells contained quite low 
levels of ALT and AST activity in control group that significantly increased in culture 
medium of HepaRG cells exposed to APAP reaching its peak with 20 mM (Fig. 6B-C). 
As an indicator of cell death (160), TUNEL staining was tested. TUNEL staining 
detects several types of cell death, including necrosis, apoptosis and necroptosis. Cell 
death significantly increased after exposure of APAP, however, the number of TUNEL-
positive cells was similar between 10 and 20 mM APAP (Fig. 6D-E). This observation 
associated with the increase of apoptotic DNA fragmentation was also validated by 






Figure 6. Cytotoxicity of different concentrations of acetaminophen (APAP) in HepaRG 
cells. (A) Cell viability was determined by CCK8 assay. (B) Supernatant ALT levels. (C) 
Supernatant AST levels. (D) Representative TUNEL staining performed on coverslips. (E) 
Quantification of TUNEL positive cells per view field was shown. (F) Protein levels of cleaved 
caspase 3 were determined by Western Blot. GAPDH was used as a loading control. Data are 
expressed as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Arrows denote 
positive cells. 
 
6.2 APAP leads to loss of tight junctions (TJs) and lipid accumulation in HepaRG 
cells 
Elevations of hepatic triglycerides have been reported in APAP toxicity and likely 
reflect a switch in energy metabolism that occurs during cytotoxicity (161). HepaRGs 
displayed increasing concentrations of ORO staining after APAP exposure, more 
evident at an APAP dose of 5 mM and 10 mM (Fig. 7A). Tight junctions (TJs) maintain 
differentiated functional polarity and xenobiotic metabolic competence of hepatocytes. 
APAP exposure to HepaRGs caused TJ destabilization which was directly proportional 
to APAP concentration, and confirmed via disruption of the TJ-specific protein zonula 
occludens-1 (ZO-1) by immunofluorescence and immunoblot (Fig. 7B-D). ZO-1 is 
located in the intracellular membrane and works as a scaffold protein cross-linking and 
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anchoring TJ strand proteins to the actin cytoskeleton (162). Confocal microscopy 
demonstrated continuous, membranous staining of ZO-1 in normal HepaRGs and 
reduced intensity with increasing APAP. In consistent, western blot data showed that 
ZO-1 protein expression was down-regulated with increasing concentration of APAP. 
Altogether, our results using human HepaRGs show that a concentration of 10 mM 
APAP suffices to induce a cytotoxicity, apoptotic cell death, disruption of TJs and lipid 
accumulation in human hepatocytes. 
 
Figure 7. Cytotoxicity of high concentrations of acetaminophen (APAP) lead to lipid 
accumulation and loss of tight junctions (TJs) in HepaRG cells. (A) Representative ORO 
staining performed on coverslips. (B) Representative ZO-1 staining performed on coverslips. 
(C) Quantification of ZO-1 positive cells per view field was shown. (D) Protein levels of ZO-
1 were determined by Western Blot. GAPDH was used as a loading control. Data are expressed 
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as mean ± SEM (*p<0.05, ***p<0.001, ****p<0.0001).  
 
6.3 A sublethal dose of APAP (300 mg/kg) induces liver damage, hepatocyte 
necrosis, loss of TJs in WT mice 
C57BL/6J WT mice were fasted overnight and treated with low to high doses of 
APAP (0-300 mg/kg) by intraperitoneal injection. Twenty-four hours after 
intraperitoneal injection, mice were sacrificed and liver damage was assessed. 
Diagnostic liver function tests were performed to analyzed serum markers of liver 
damage and cytosolic enzyme leakage. ALT, AST and LDH were markedly increased 
in treated mice compared to the controls in a dose-dependent fashion, indicating the 
expected APAP-mediated liver damage (Fig. 8A-C). Centrilobular hepatocellular 
necrosis is the hallmark lesion of acetaminophen injury. As we expected, centrilobular 
necrosis was more histologically evident after exposure to 300 mg/kg APAP for 24 h 
(Fig. 8D). TUNEL IF staining proved significant hepatocyte death in necrotic areas as 
a result of APAP toxicity, specifically 24 h after 300 mg/kg APAP (Fig. 8E-F). Caspase 
3 is a typical caspase protein in caspase-independent apoptotic signaling pathway, 
where it is responsible for chromatin condensation and DNA fragmentation. Cleaved 
caspase 3 immunoblot further confirmed the results of TUNEL staining (Fig. 8G). In 
addition, ZO-1 IF was progressively lost with increasing APAP dose and more 
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Figure 8. A sublethal dose of APAP (300 mg/kg) triggers strong hepatic damage in WT mice. 
(A) Serum ALT level represented as U/L. (B) Serum AST level represented as U/L. (C) Serum LDH 
level represented as U/L. (D) Representative H&E staining performed on paraffin liver sections. (E) 
Representative TUNEL staining performed on frozen liver sections. (F) Quantification of TUNEL 
positive cells per view field was shown. (G) Protein levels of cleaved caspase 3 were determined 
by Western Blot. (H) Representative ZO-1 staining performed on frozen liver sections. (I) 
Quantification of ZO-1 positive cells per view field was shown. (J) Protein levels of ZO-1 were 
determined by Western Blot. GAPDH was used as a loading control. Data are expressed as mean ± 
SEM (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Arrows denote positive cells. 
 
6.4 A sublethal dose of APAP induces oxidative stress in WT mice 
APAP overdose depletes cellular GSH and induces mitochondrial oxidative stress. 
A considerable amount of research has shown that together with lipotoxicity, the 
generation of free radicals such as superoxide, are pivotal for APAP-induced 
hepatocyte necrosis (163). During the past decade, several fluorescent dyes have been 
widely used to quantify cellular O2
•− and H2O2, for example by DHE. DHE can freely 
permeate cell membrane and be oxidized by cellular O2
•− to produce two red fluorescent 
products, namely ethidium (E+), which is typically formed by a non-specific redox 
reaction, and 2-hydroxyethidium (2-OH-E+), a specific adduct of cellular O2
•−. Recently, 
many investigators use fluorescent microscopy to measure DHE-derived fluorescence 
in the artery from diabetes (164), hypertension (165) and atherosclerosis (166). 4-
hydroxynonenal (4-HNE) is one major product of lipid peroxidation. 4-HNE-protein 
adducts are contained in hepatocytes displaying intact morphology, and reliable 
biomarkers of hepatic lipid peroxidation associated with liver injury. In our study, DHE 
IF and 4-HNE IHC staining were significantly elevated 24 h after 300 mg/kg APAP in 
C57BL/6J WT mice while no observed in control group (Fig. 9A-B; Fig. 9C).  
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Figure 9. A sublethal dose of APAP (300mg/kg) triggers oxidative stress in WT mice. (A) 
Representative DHE staining performed on frozen liver sections. (B) Quantification of DHE 
positive cells per view field was shown. (C) Representative 4HNE staining performed on 
paraffin liver sections. Data are expressed as mean ± SEM (****p<0.0001). Arrows denote 
positive cells. 
 
6.5 A sublethal dose of APAP induces accumulation of triglyceride and hepatic 
steatosis in WT mice 
Some drugs can induce microvesicular steatosis. Liver pathology shows the 
presence of numerous lipid droplets, which can be stained with Oil Red O (167). ORO 
is a fat-soluble diazo dye used for staining of triglycerides and lipids on frozen sections 
and lipoproteins on paraffin sections. It has the appearance of a red powder. In our study, 
minimal staining for ORO was detected in the liver sections of the mice treated with 
PBS in ORO immunohistochemical images of mouse liver. In contrast, ORO staining 
was localized to the regions surrounding the hepatic vein in WT mice challenged with 
300 mg/kg APAP. The pattern of ORO staining with the localization of ORO to the 
centrilobular regions suggested that lipid deposition occurred at 24 h after APAP 
toxicity. In consistent with the result of ORO staining, liver triglyceride content had a 
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significant increase in WT mice challenged with 300 mg/kg APAP, reflecting moderate 
steatosis and lipid accumulation due to APAP hepatotoxicity in murine (Fig. 10A-C).  
 
Figure 10. APAP (300mg/kg) induces hepatic steatosis and lipogenesis in wildtype mice. 
(A) Representative ORO staining performed on frozen liver sections. (B) Quantification of 
ORO positive cells per view field was shown. (C) Liver triglycerides content was tested by 
enzymatic colorimetric tests. Data are expressed as mean ± SEM (*p<0.05, **p<0.01, 
***p<0.001， ****p<0.0001).  
 
6.6 A sublethal dose of APAP induces immune infiltration and inflammation in 
WT mice 
A potential source of oxidative stress is inflammatory cells recruited into the liver 
and liver resident KCs. The development of APAP hepatotoxicity is closely associated 
with the activation of the innate immune response involving the upregulation of 
proinflammatory cytokines, including IL-6, TNFα and IL-1β. Therefore, we 
investigated the characterization of hepatic inflammation in the WT mice. Some 
isoforms are often used as markers to identify and distinguish between different types 
of immune cells. For example, CD45 is a receptor-linked protein tyrosine phosphatase 
that is expressed on all leucocytes. CD11b is expressed on the surface of many 
leukocytes like monocytes, neutrophils, natural killer cells and so on. And F4/80 has 





































































been established as one of the most specific cell-surface markers for macrophages. 
Interestingly, the number of CD45, CD11b and F4/80 positive cells increased in a dose-
dependent fashion (Fig. 11A-F). The mRNA expression levels of proinflammatory 
cytokines in mouse liver were determined by RT-qPCR. As shown in Fig. 11G-H, the 
mRNA levels of Tnfα and IL-1β were elevated in WT mice after 300 mg/kg injection 
(Fig. 11G-H). Altogether, our data suggest inflammation was initiated in liver of WT 
mice, with a characteristic recruitment of inflammatory cells. 
In general, our data show that a sublethal dose of APAP (300 mg/kg) induces liver 
damage, cell death, disruption of TJs, lipid accumulation, and immune cell infiltration 
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Figure 11. APAP (300mg/kg) induces inflammation and activation of inflammasome in 
WT mice. (A) Representative CD45 staining performed on frozen liver sections. (B) 
Representative CD11b staining performed on frozen liver sections. (C) Representative F4/80 
staining performed on frozen liver sections. (D) Quantification of CD45 positive cells per view 
field was shown. (E) Quantification of CD11b positive cells per view field was shown. (F) 
Quantification of F4/80 positive cells per view field was shown. (G) mRNA level of Tnfα was 
determined by RT-qPCR. (H) mRNA level of IL-1β was determined by RT-qPCR. Data are 
expressed as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Arrows denote 
positive cells.  
 
6.7 Activation of the UPR and JNK1/2 is characteristic of human and murine 
APAP-mediated hepatotoxicity 
Since we speculated that APAP-induced ER stress might lead to the deleterious 
effects observed both in HepaRGs and in vivo, we subsequently investigated activation 
of the UPR response after exposure to APAP in these conditions. The UPR is activated 
in response to an accumulation of unfolded or misfolded proteins in the lumen of ER. 
As we expected, we found that the UPR was transcriptionally active in both human 
HepaRGs and in mice after exposure to a sublethal dose of APAP, including the splicing 
of Xbp1 (Fig. 12A-B). These results were supported by immunoblotting analyses of 
various UPR components in HepaRGs (0-20 mM) and WT mice (0-300 mg/kg). 
Phosphorylation of IRE1α, accumulation of CHOP in the nucleus, loss of BiP/GRP78 
and splicing of XBP1 were observed 24 h after exposure to 10 mM APAP in culture 
HepaRG cells and 24 h after injection of 300 mg/kg APAP in mice (Fig. 12C). 











































































































































Extensive experimental evidences show that JNK activation and its translocation 
to mitochondria attributes to APAP hepatotoxicity (86). Moreover, JNK activation is 
sustained in severe ER stress-induced cell death (91). Therefore, we evaluated the 
activation of the JNK1/2 signaling pathway in HepaRGs (0-20 mM) and WT mice (0-
300 mg/kg). Interestingly, phosphorylation of JNK1 and JNK2 were evident 24 h after 
exposure to 10 mM APAP in culture HepaRG cells and 24 h after injection of 300 
mg/kg APAP in mice (Fig. 12D). The expression of activated JNK were significantly 
increased, which indicated the JNK signaling pathway was activated in APAP-induced 
hepatotoxicity. 
In summary, our data indicates that transcriptional and transductional activation 
of the UPR and phosphorylation of JNK1/2 are major events in the hepatotoxic response 
to APAP both in human cells and in murine liver. 
 
 




















































































Figure 12. APAP overdose triggers ER stress and cell death 24 h after APAP challenge in 
HepaRG cells (0-20 mM) and WT mice (0-300 mg/kg). (A) mRNA level of sXbp1/uXbp1 in 
HepaRG cells was determined by RT-qPCR. (B) mRNA level of sXbp1/uXbp1 in WT mice was 
determined by RT-qPCR. (C) Protein levels of pIRE1α, IRE1α, BiP, sXBP1, uXBP1, CHOP in 
HepaRG cells and WT mice were determined. (D) Protein levels of pJNK, JNK, pJNK1, JNK1, 
pJNK2, JNK2 in HepaRG cells and WT mice were determined. GAPDH was used as a loading 
control. Data are expressed as mean ± SEM (*p<0.05, ****p<0.0001). 
 
6.8 Generation of knockout mice 
Signaling through IRE1α is the most conserved one among the three arms of UPR, 
which is worthy of our more attention. Besides, Xbp1 gene is required for optimal 
cytokine expression in macrophages and controls the inflammatory response (137). 
Therefore, in our study, we not only used WT mice, but also established Xbp1 specific 
hepatic-knockout mice with C57BL/6 background to investigate Xbp1 specific function 
in APAP-induced liver damage. We crossed Xbp1f/f mice with Alb-cre mice expressing 
Cre recombinase to achieve hepatocyte specific deletion of XBP1. The correct genotype 
and the effective excision of the genes of Xbp1 was confirmed on DNA level by PCR 
analysis of tails from newborn mice tails. WT-Xbp1 allele was detected in agarose gel 
electrophoresis as a 183-bp DNA fragment or a 141-bp DNA fragment for floxed-Xbp1 
allele. Mutant allele for Albcre was observed as a 390-bp band in gel electrophoresis 
and an artifact band of 150-bp was frequently present from the mutant allele, while wild 
type allele was a 351-bp band (Fig. 13A). We also extracted proteins from frozen mouse 
liver and did western blot with XBP1 antibody. The protein expression of XBP1 in the 


























13B). Low residual protein expression of XBP1 in liver of Xbp1Δhepa mice might be due 
to the expression in non-parenchymal cells.  
 
Figure 13. Proof of Xbp1 deletion in Xbp1Δhepa mice. (A) Agarose gel showing the respective PCR 
results from mice tails DNA derived from Xbp1Δhepa and Xbp1f/f mice. (B) Protein levels of XBP1 
in the liver were determined. GAPDH was used as a loading control. 
 
6.9 Ablation of Xbp1 in hepatocytes reduces APAP-induced hepatic damage 
Since the UPR was activated after 24 h of exposure to 10 mM APAP in human 
HepaRG cells and a sublethal dose ≥300 mg/kg APAP in WT mice, and the splicing of 
Xbp1 indicated that the IRE1-XBP1 branch of the UPR response might be involved in 
DILI, we generated mice with specific deletion of Xbp1 in hepatocytes (Xbp1∆hepa). 
Littermate Xbp1f/f mice were used as controls. First, we focused on the phenotypes of 
Xbp1∆hepa mice. Xbp1∆hepa mice were viable, grew smoothly and looked completely 
normal. Then we checked the protein expression of the IRE1α-XBP1 arm. Importantly, 
untreated Xbp1∆hepa livers displayed hyperactivation of IRE1α (Fig. 14A), which is 
consistent with the results of Hur (134). The ablation of Xbp1 led to feedback activation 
of its upstream enzyme IRE1α in the liver. 
8-12 weeks old Xbp1Δhepa mice and its littlemates Xbp1f/f mice were fasted 
overnight and challenged with a sublethal dose of APAP. Mortality in Xbp1Δhepa group 
was dramatically reduced after a single dose of 500 mg/kg (Fig. 14B). Only 60% mice 





















was up to 90%. Whilst the levels of serum transaminases markedly increased in Xbp1f/f 
animal, Xbp1∆hepa displayed only a modest induction of serum ALT, AST and LDH 
levels, 24 h after APAP treatment (Fig. 14C-E). Macroscopic and histological analysis 
of the liver revealed markedly reduced liver injury in Xbp1∆hepa mice compared with 
Xbp1f/f animals that exhibited severe centrilobular necrosis and hemorrhage (Fig. 14F) 
and significantly higher TUNEL-positive cells (Figs. 14G-H), demonstrating that Xbp1 
deficiency protected mice from APAP-induced hepatotoxicity. Caspase 3 plays a 
central role in the execution phase of cell apoptosis, which is activated to cleaved 
caspase-3 in the apoptotic cell both by extrinsic and intrinsic pathways. Xbp1 knockout 
mice displayed lower protein expression level of CC3 in the liver compared to Xbp1f/f 
























































































Figure 14. Ablation of Xbp1 in hepatocytes reduces APAP-induced hepatic damage 24 h after 
APAP challenge. (A) Protein levels of pIRE1α and IRE1α in the liver were determined. (B) 
Survival of Xbp1∆hepa and Xbp1f/f mice (n=10) after APAP administration. P < 0.05 (Mantel–Cox 
test). (C) Serum ALT level represented as U/L. (D) Serum AST level represented as U/L. (E) Serum 
LDH level represented as U/L. (F) Representative H&E staining performed on paraffin liver 
sections. (G) Representative TUNEL staining performed on frozen liver sections. (H) 
Quantification of TUNEL positive cells per view field was shown. (I) Protein levels of CC3 in the 
liver were determined. GAPDH was used as a loading control. Data are expressed as mean ± SEM 
(***p<0.001, ****p<0.0001, ##p<0.01, ###p<0.001). Arrows denote positive cells.  
 
6.10 Ablation of Xbp1 in hepatocytes reduces oxidative stress at 24 h after APAP 
challenge 
APAP-induced acute liver injury is initiated by N-acetyl-p-benzoquinone imine 
(NAPQI), generated by several CYP450 isoenzymes, mainly CYP2E1 and CYP3A4 
CC3
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(168). To investigate the mechanism by which XBP1 regulates APAP metabolism, we 
checked the expression of CYP450 enzymes. CYP2E1 protein levels visibly decreased 
after APAP overdose in Xbp1f/f mice, but they were clearly at low expression in basal 
conditions and after APAP challenge in Xbp1∆hepa mice (Fig. 15A-B). The CYP2E1 
IHC staining also showed decreased number of CYP2E1 positive cells in livers after 
APAP toxicity in Xbp1f/f mice and low number of CYP2E1 positive cells in Xbp1∆hepa 
group.  
CYP2E1 metabolism leads to the generation of ROS including lipid peroxidation 
- measured by 4-HNE IHC (Fig. 15C), a well-established consequence of severe ER 
stress. The positive cells of 4-HNE staining were significantly reduced in Xbp1∆hepa 
compared with Xbp1f/f mice, 24 h after APAP overdose. Heme oxygenese-1 (HO-1) is 
a stress-inducible enzyme that provides antioxidant protection and exerts marked anti-
inflammatory actions (169). HO-1 is activated by various oxidative stress stimuli, and 
several studies demonstrated the up-regulation of hepatic HO-1 expression consequent 
to APAP toxicity (170, 171). In current study, APAP significantly increased the mRNA 
expression of HO-1 in Xbp1f/f mice, and ablation of Xbp1 in hepatocytes significantly 
reduced HO-1 level (Fig. 15D) 
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Figure 15. Ablation of Xbp1 in hepatocytes reduces oxidative stress at 24h after APAP 
challenge. (A) Protein levels of CYP2E1 were determined by Western Blot. GAPDH was used 
as a loading control. (B) Representative CYP2E1 staining on paraffin liver sections. (C) 
Representative 4HNE staining performed on paraffin liver sections. (D) mRNA level of heme 
oxygenese-1 (HO-1) was determined by RT-qPCR. Data are expressed as mean ± SEM 
(****p<0.0001, ####p<0.0001).  
 
6.11 Ablation of Xbp1 in hepatocytes maintains TJs at 24 h after APAP challenge 
Increased ROS, as a result of APAP hepatotoxity, disrupt hepatic TJs (172). 
Dysfunction of cell-cell tight junction adhesions is a major feature in APAP-induced 
DILI. To assess whether TJ-destabilization occurs, we analyzed ZO-1 expression in 
livers of Xbp1f/f and Xbp1∆hepa mice treated with APAP. Both Xbp1f/f and Xbp1∆hepa mice 
treated with DMSO (vehicle) maintained normal cell polarity and adhesion as shown 
by ZO-1 IF (Fig. 16A). ZO-1 expression characterized by IF exhibited mostly 
continuous, membranous staining that outlined hepatocyte cords in all areas. However, 
APAP caused dramatic decreased in the expression of ZO-1 in Xbp1f/f mice, but to a 
lesser extent in Xbp1∆hepa mice. Quantification of ZO-1 positive area validated these 
results (Fig. 16B). ZO-1 protein expression showed similar trend of staining results. 
ZO-1 protein expression was significantly decreased in livers due to APAP toxicity, but 
the level in Xbp1∆hepa mice was higher than that in Xbp1f/f mice, indicating ablation of 
Xbp1 in hepatocytes maintained cellular polarity and the blood-biliary barrier (Fig. 
16C). 
Altogether, this set of data indicates deletion of Xbp1 in liver parenchymal cell 
(LPC) protects against acute liver injury, hepatocellular necrosis, the generation of ROS 



























Figure 16. Ablation of Xbp1 in hepatocytes maintains tight junction at 24h after APAP 
challenge. (A) Representative ZO-1 staining performed on frozen liver sections. (B) 
Quantification of ZO-1 positive cells per view field was shown. (C) Protein levels of ZO-1 
were determined by Western Blot. GAPDH was used as a loading control. Data are expressed 
as mean ± SEM (****p<0.0001, ###p<0.001).  
 
6.12 Xbp1∆hepa livers show decreased UPR and JNK1/2 activation in response to 
APAP  
As shown by us (Fig. 14A) and others (134), loss of Xbp1 in hepatocytes causes 
hyperactivation of IREα. Therefore, we next sought to investigate the UPR after APAP 
in Xbp1∆hepa mice. APAP toxicity can promote the occurrence of ER stress and the 
activation of UPR. So we analyzed protein expression of UPR markers 24 h after APAP 
injection. Whilst APAP did not increase IREα phosphorylation much in Xbp1f/f mice, 
protein levels were overexpressed in mice with hepatocyte-specific deletion of Xbp1 
(Xbp1∆hepa) (Fig. 17A). In turn, APAP increased CHOP and BiP/GRP78 protein levels 
in Xbp1f/f compared with Xbp1∆hepa livers (Fig. 17A). Expectedly, the levels of uXBP1 
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knockout mice recover better that flox mice after ER stress. 
JNK is activated by APAP and plays a crucial role in the hepatotoxicity (86, 173-
175). To determine the effect of Xbp1 knockout on JNK activation, we examined the 
JNK signaling pathway in liver tissues by immunoblotting 24 h after APAP treatment. 
In WT mice, JNK phosphorylation was strongly induced at 6 h after APAP treatment, 
and then declined at the 24 h time point. Similar to WT mice, low but detectable protein 
expression of pJNK was found in Xbp1f/f mice after APAP treatment, whereas lack of 
JNK induction was characteristic of Xbp1∆hepa livers at this time point (Fig. 17B). JNK1 
and JNK2 activation was similar to JNK and was very mild in both Xbp1f/f and Xbp1∆hepa 
24 h after APAP treatment (Fig. 17B), which might contribute to the protection of 
Xbp1-deficient mice from APAP-induced toxicity. Given that CYP2E1 generates ROS 
by metabolizing a variety of substrates (176), it is conceivable that the reduction of 





Figure 17. Ablation of Xbp1 in hepatocytes increases the expression of pIRE1α, reduces 
the expression of BIP and CHOP and affects JNK activation. (A) Protein levels of pIRE1α, 
IRE1α, BiP, sXBP1, uXBP1, CHOP were determined. (B) Protein levels of pJNK, JNK, pJNK1, 
JNK1, pJNK2, JNK2 were determined. GAPDH was used as a loading control. 
 
6.13 Immune infiltration, inflammation and inflammasome activation are 
ameliorated in APAP-treated Xbp1∆hepa animals 
The presence of an inflammatory infiltrate is obvious both histologically and 
biochemically in APAP livers, also contribute to APAP hepatotoxicity (138). Therefore, 
we next examined the impact of inflammation in the mechanisms contributing 
hepatocyte death in APAP-mediated hepatotoxicity. Leukocytes, monocyte and 












































treatment in Xbp1f/f mice according to CD11b, CD45 and F4/80 IF staining. However, 
the number of CD45-positive cells was significantly reduced in Xbp1∆hepa mice 
compared to Xbp1f/f mice. No differences were found in CD11b, F4/80-positive cells 
(Fig. 18D-F) between two mice after exposure to APAP toxicity. Concomitantly, 
mRNA transcripts for Tnfα indicated significantly decreased inflammation in Xbp1∆hepa 
compared with Xbp1f/f livers, 24 h after APAP treatment (Fig. 18G). 
The NLRP3 inflammasome is critical for host defenses against injuries and has 
been linked to the pathogenesis of several inflammatory disorders. Inflammasomes are 
intracellular signaling platforms that activate caspase 1, which then cleaves pro-
interleukin-1β (pro-IL-1β) into active IL-1β (177). To investigate the mechanisms of 
inflammasome which play a role in Xbp1∆hepa mice, we analyzed the expression of 
markers of inflammasome. Noticeably, the mRNA expressions of IL-1β and Nrlp3 were 
significantly lower in Xbp1∆hepa compared with Xbp1f/f livers, 24 h after APAP 
treatment (Fig. 18H-I). Furthermore, overexpression of NLRP3 and IL-1β protein was 
observed in APAP-treated Xbp1f/f compared to Xbp1∆hepa livers in western blot (Fig. 
18J), indicating that immune infiltration, inflammation and inflammasome activation 
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Figure 18. Ablation of Xbp1 in hepatocytes alleviates inflammatory response and prevents 
hepatic activation of the NLRP3 inflammasome. (A) Representative CD45 staining 
performed on frozen liver sections. (B) Representative CD11b staining performed on frozen 
liver sections. (C) Representative F4/80 staining performed on frozen liver sections. (D) 
Quantification of CD45 positive cells per view field was shown. (E) Quantification of CD11b 
positive cells per view field was shown. (F) Quantification of F4/80 positive cells per view 
field was shown. (G) mRNA level of Tnfα was determined by RT-qPCR. (H) mRNA level of 
IL-1β was determined by RT-qPCR. (I) mRNA level of Nlrp3 was determined by RT-qPCR. 
(J) Protein levels of NLRP3, pro-IL-1β, mature IL-1β were determined. GAPDH was used as 
a loading control. Data are expressed as mean ± SEM (**p<0.01, ***p<0.001, ****p<0.0001, 
#p<0.05, ##p<0.01, ####p<0.0001). Arrows denote positive cells. 
 
6.14 Ablation of Xbp1 reduces the lipid accumulation in the liver 
Current data reinforce the role of XBP1 in hepatic lipid synthesis via both UPR 
and non-UPR pathways. sXbp1 can directly increase the expression of several lipogenic 
genes, such as diacylglycerol acetyltransferase and acetyl-CoA carboxylase 2 (178). 



































































































































































metabolism genes controlled by regulated IRE1-dependent decay (RIDD), such as 
angiopoietin-like 3 (ANGPTL3) and carboxylesterase 1 (CES1) (179, 180). As we 
expected, from the ORO staining, Xbp1∆hepa mice did not develop hepatic steatosis as 
did Xbp1f/f mice due to APAP, less lipid accumulation in the view fields. Morphometric 
analysis was used to quantify this difference to determine the fractional area occupied 
by vacuoles in each liver slice. After quantification, there were statistically differences 
between two groups after APAP injection (Fig. 19A-B). Hepatic triglyceride 
accumulation is a well-established consequence of severe ER stress (181). We find that, 
24 h after exposure to APAP, Xbp1f/f mice showed a dramatic increase in hepatic 
triglyceride content while Xbp1∆hepa mice were protected (Fig. 19 C). 
 
Figure 19. Ablation of Xbp1 reduces the lipid accumulation in the liver. (A) Representative 
ORO staining performed on frozen liver sections. (B) Quantification of ORO positive cells per 
view field is shown. (C) Liver triglycerides content was tested by enzymatic colorimetric tests. 
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6.15 Loss of Xbp1 in hepatocytes promotes autophagy after APAP treatment 
Considerable evidence has shown that ER stress initiates autophagy, a cellular 
degradation process initiated in response to stress, which attempts to restore 
homeostasis through the catabolic lysis of unfolded/misfolded proteins (182). 
Chemicals that directly induced ER stress, such as tunicamycin and thapsigargin have 
been shown to induce autophagy (183). The IRE1α pathway deserves the most attention, 
since it has already published that the IRE1α pathway is involved in autophagy directly 
induced by stressing ER (184). To assess whether autophagy is activated in mice with 
hepatocyte-specific deletion of Xbp1, transmission electron microscopy (TEM) was 
performed. Severe necrosis and mitochondrial damages in hepatocytes of mice after 
APAP treatment was shown in TEM images, and the accumulation of abundant 
autophagosomes, the characteristics of autophagy-related ultrastructures, indicated the 
activation of autophagy in livers of Xbp1∆hepa mice following APAP treatment. 
Moreover, the number of autophagosomes was much bigger compared to Xbp1f/f 
animals. At the same time, the hepatic parenchyma of Xbp1f/f animals was 
predominantly necrotic (Fig. 20A).  
 
Figure 20. Ablation of Xbp1 promotes autophagy. (A) TEM images of hepatocyte of control 
group and acetaminophen-treated group. APAP toxicity induced evident necrosis and severe 
mitochondrial damages in livers of Xbp1f/f animals while abundant autophagosomes were 
formed in Xbp1∆hepa mice. N = nucleus, M = mitochondria, A = autophagosome, L = lipid, ER 
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6.16 APAP treatment triggers autophagy in Xbp1∆hepa mice via AMPK activation 
and AKT inhibition 
ER stress activation is frequently accompanied by Ca2+ release into the cytosol 
which leads to the activation of several Ca2+-regulated signaling pathways (185). One 
of the mechanisms connecting Ca2+ release from the ER and autophagy is the 
stimulation of AMPK, and inhibition of the AKT pathway. Next, we tried to discover 
the mechanism of autophagy in Xbp1∆hepa mice. The mRNA expression of autophagy 
markers Atg5 was upregulated and p62 downregulated according to qPCR results (Fig. 
21A-B). To determine the possible role of Xbp1 in the regulation of autophagy and 
autophagic flux, we also measured the conversion of microtubule-associated protein 
light chain 3 (LC3) from the form I to II, as well as P62 expression in Xbp1∆hepa and 
Xbp1f/f mice. LC3 and P62 are commonly used markers for detecting the level of 
autophagy. Compared to Xbp1f/f mice, the degradation of P62 and the conversion of 
LC3-I to LC3-II were promoted in Xbp1∆hepa mice. Since autophagy may be one of the 
downstream positive feedback mechanisms of AMPK, protein level of pAMPK was 
also checked by immunoblotting, and significantly increased in livers of Xbp1∆hepa mice 
following APAP treatment, consequently inhibiting pAKT (Fig. 21C). Activated 
AMPK will initiate a protective feedback mechanism to maintain ATP production and 
promote cell survival. The data suggest that ablation of Xbp1 may effectively elevate 



















































Figure 21. Ablation of Xbp1 promotes autophagy via the AMPK activation and AKT inhibition. 
(A) mRNA level of Atg5 was determined by RT-qPCR. (B) mRNA level of p62 was determined by 
RT-qPCR. (C) Protein levels of pAMPK, AMPK, pAKT, AKT, P62, LC3I/II were determined. 
GAPDH was used as a loading control. Data are expressed as mean ± SEM (*p<0.05, #p<0.05).  
 
6.17 STF-083010 mitigates liver injury induced by a sublethal dose of APAP 
To further study the role of IRE1α-XBP1 signaling in APAP-induced liver injury, 
we also used inhibitor to suppress this arm in vivo. STF-083010 is an inhibitor of the 
endonuclease activity of IRE1α without affecting its kinase activity. STF-083010 can 
block Xbp1 mRNA splicing and XBP1 activity after ER stress both in vivo and in vitro. 
It has been reported that STF-083010 protected against thioacetamide  (TAA)-induced 
liver injury (186) and carbon tetrachloride (CCl4)-induced liver fibrosis (187). In our 
case, we aimed to check the phenotype after blocking Xbp1 in hepatocytes. This study 
analyzed the effect of STF-083010 on serum biological parameters. Obviously, STF-
083010 extenuated the elevation of ALT, AST and LDH levels induced by a sublethal 
dose of APAP (Fig. 22A-C). The effects of STF-083010 on hepatic histopathological 
damage were presented by H&E staining (Fig. 22D). Extensive necrosis areas and 
infiltration of immune cells were observed in APAP-treated liver tissue sections while 
STF-083010 manifestly mitigated APAP-induced hepatic necrosis and inflammation. 
According to the quantification, the necrotic area in APAP+STF-083010 group was 
significantly decreased than that in only APAP group (Fig. 22E). It is possible that this 























response. As an important part of APAP hepatotoxicity, we are going to further explore 
its specific mechanism in subsequent studies in the future. 
 
 
Figure 22. Effects of STF-083010 on liver injury and inflammation induced by a sublethal 
dose of APAP injection. (A) Serum ALT level represented as U/L. (B) Serum AST level 
represented as U/L. (C) Serum LDH level represented as U/L. (D) Representative H&E staining 
performed on paraffin liver sections. (E) Quantification of necrotic area per view field is shown. 


































































































































































































Acetaminophen overdose-induced liver injury threatens human health and 
restricts drug use. The hepatic injury model induced by APAP occupies an 
indestructible position in the study of liver disease. The identification of the molecular 
mechanisms could provide possible therapeutic strategy. Many important steps in 
APAP toxicity, including the production of NAPQI and depletion of GSH, have been 
known for decades. However, many controversies around APAP mechanisms still 
exist and need to be explored. In our study, we have demonstrated that Xbp1 gene in 
the hepatocytes is crucial for protecting against APAP-induced hepatotoxicity. The 
knockout of Xbp1 resulted in the upregulation of autophagy though activation of 
AMPK, then to decrease liver inflammation and oxidative stress.  
It was reported that the threshold for a single dose of APAP to induce 
hepatotoxicity in humans was estimated to be approximately 250 mg/kg (188). After 
exposure to overdosing APAP, the metabolized NAPQI depleted hepatic GSH, 
leading to necrosis of hepatocytes and acute liver injury. HepaRGs provide a 
physiologically-relevant in vitro liver model, with intact drug metabolism, and 
functional polarity, delineated by junctional complexes. Concentrations of APAP 
higher than 10 mM in human HepaRGs triggered significant cytotoxicity, loss of TJs 
and lipid accumulation. Mechanisms of APAP hepatotoxicity are reported to be 
similar in both human and mice. Indeed, clinically-relevant mechanisms of APAP 
toxicity in human hepatic cells are consistent with murine studies of APAP 
hepatotoxicity (158). Mice are more commonly used than the other species, and mice 
with APAP model is considered to be the golden model for studying the mechanisms 
for APAP-induced hepatotoxicity and searching for effective therapies for liver injury. 
Our study was carried out with male mice, because their metabolism remains stable 
compared to the physiological variations of female mice (189). Prior to injection, 
animals were fasted, as fasting improves the uniformity of drug administration, 
reduces APAP glucuronidation and potentiates hepatotoxicity (190). 200 to 400 
mg/kg APAP is reported to have liver toxicity in mice (191, 192). Therefore, in our 
study, we used different doses of APAP (from 75 mg/kg to 300 mg/kg) to assess the 




parenchymal necrosis and massive hepatocyte death were observed, accompanied by 
the increase of ALT, AST and LDH. Activity of aminotransferase is a traditional 
biomarker of liver injury (193). Thus, the dosage at 300 mg/kg were verified that 
could induce evident hepatic injury. APAP induces not only necrosis, but also 
apoptosis and necroptosis. In our thesis, we aimed to show that sublethal application 
of APAP induces significant hepatocyte death. However, we did not check the type 
of cell death, which we plan to do for the paper submission. 
 In hepatocytes, the ER is the major site for protein synthesis, folding and 
metabolism. It has been reported that APAP overdose can induce the activation of 
three arms of UPR. We prove that IRE1α-XBP1-CHOP signaling cascade is involved 
in APAP-induced liver damage. ER stress is induced late after APAP intoxication 
(500 mg/kg) in murine models, and becomes significant 12 h following APAP 
administration (122), while Hur did not observe the activation of IRE1α or other UPR 
branches in the liver of APAP-treated mice within 8 h after APAP injection (134). In 
our study, we observed increased mRNA and protein levels of sXBP1 both in vitro 
and in vivo, indicating the IRE1α-XBP1 arm of the UPR might be activated in APAP-
mediated hepatotoxicity. Compared with other two modulators of UPR, PERK and 
ATF6, IRE1α appears to be activated when the unfolded proteins directly bind to it 
rather than by disassociation with BiP (194). Upon APAP-mediated ER stress, PERK, 
IRE1α and ATF6 induce signal transduction events, which increases the expression 
of ER molecular chaperones, inhibits proteins enter to the ER by preventing mRNA 
translation and stimulates the retrograde transport of misfolded proteins from the ER 
into the cytosol, thereby alleviating the accumulation of misfolded proteins in the ER. 
IRE1α oligomerization and phosphorylation initiates splicing of the mRNA encoding 
Xbp1, promoting restoration of homeostasis and cytoprotection (127). When the 
various UPR-induced mechanisms fail to relieve stress, intrinsic and extrinsic 
pathways for apoptosis are activated (130). A downstream transcription repressor of 
UPR, CHOP is activated (130). Once activated, CHOP translocates to the nucleus, 
where inhibits the expression of anti-apoptotic genes and activates pro-apoptotic 




From our data, CHOP and BiP are also activated at high dose of APAP in human 
HepaRGs and in animals 24 h after a sublethal exposure to APAP in vivo. 
In APAP-induced hepatocyte death or ALF, the mitochondria are the primary 
targeted organelles. Oxidative stress and lipid peroxidation mediated by production 
of ROS have been implicated as an important cause of DILI (161). The intermediate 
metabolites NAPQI leads to mitochondrial dysfunction by altering mitochondrial 
membrane permeability, increasing ROS formation and diminishing the capacity of 
the electron transportation system. The release of mitochondrial ROS induces the 
activation of JNK within a short period, and a feedforward self-sustaining signaling 
pathway referred as the JNK amplification loop would maintain sustained JNK 
activation (91, 92), directly leading to liver damage and dysfunction (93). In fact, JNK 
is activated by APAP and plays a crucial role in the hepatotoxicity (86, 173-175). In 
the liver, two JNK genes, JNK1 and JNK2, are expressed (195). Silencing of the JNK 
pathway - using the classical inhibitor SP600125 - has protective effects against 
APAP-induced liver injury, by significantly reducing necrosis both in vivo and in 
vitro (88, 196). Nevertheless, no differences in APAP hepatotoxicity in JNK1 
knockout mice were observed (173). Regarding JNK2, increased susceptibility 
towards APAP-induced liver injury was reported upon JNK2 deficiency (197), whilst 
the group of Kaplowitz showed that JNK2 disruption protected against APAP-
induced liver injury (173). In our human hepatocytes and murine model 
phosphorylation of JNK1 and JNK2 after high dose of APAP increased accompany 
the accumulation of ROS and oxidative stress. 
Meanwhile, lipid accumulation and immune infiltration and inflammation were 
also found in WT mice with 300 mg/kg APAP, agreeing with the prior reports (198). 
APAP administration inhibits fatty acid β-oxidation in mitochondria and disrupts 
lipid metabolism in the liver, ultimately leading to increased triglyceride level in the 
serum and liver. Hepatic triglycerides accumulate as a large lipid vacuole displacing 
the nucleus at the periphery of the hepatocyte. APAP-induced oxidative stress also 
provokes sterile inflammation by enhancing the production of pro-inflammatory 




trigger several pro-apoptotic molecules including caspase 3, the principle executor 
enzyme of apoptosis (200, 201). The rupture of the outer membrane and release of 
intermembrane proteins leads to DNA fragmentation, triggering the release of cellular 
contents including the potent HMGB1, nuclear DNA fragments, mitochondrial DNA, 
ATP and many others. These DAMPs also cause the transcriptional activation of pro-
inflammatory cytokines in macrophages through TLRs and inflammasome activation 
(138). 
According to the above results, ER stress and IRE1α-XBP1 axis play a vital role 
in liver injury caused by a sublethal dose of APAP. Dysregulation of the hepatic 
IRE1α-XBP1 axis have been associated with advanced liver disease in patients with 
nonalcoholic fatty liver disease (NAFLD), but the role of XBP1 in the progression of 
many liver diseases remains controversial (202). Shantel Olivares and Anne S. 
Henkel thought that failure to activate hepatic XBP1 in response to ER stress may 
promote liver disease progression on the basis of their findings, and hepatic XBP1 
may be a therapeutic target for the chronic liver disease (203). Moreover, the role of 
the IRE1α signaling in ER stress-induced apoptosis is complex and incompletely 
understood. Prolongation of IRE1α signaling has been proved to promote cell survival 
(204, 205). However, under certain diseases, activation of IRE1α is recognized to 
promote apoptosis (206, 207). Besides, activated IRE1α can also recruits TRAF2 and 
ASK1, leading to activation of JNK (208). BAK and BAX interact directly with 
IRE1α during ER stress, facilitating the activation of XBP1 and JNK (209).  
Interestingly, our results show that in Xbp1 hepatocyte-knockout mice, increased 
survival rate and reduced cell death were observed in response to a sublethal dose of 
APAP. Pharmacological inhibition of STF-083010 on IRE1α RNase activity also 
markedly reduced the levels of serum transaminases and mitigated liver injury 
induced by APAP in mice. STF-083010, a specific inhibitor of IRE1α RNase, inhibits 
both endogenous and chemically-induced Xbp1 splicing without affecting IRE1α 
phosphorylation. It has been reported that STF-083010 exerted anti-oxidant and anti-
inflammation capability in liver injury (187, 210). Moreover, STF-083010 facilitated 




IRE1α RNase inhibitor STF-083010 had a protective effect against APAP 
hepatotoxicity, but its specific mechanism remains to be further explored in 
subsequent studies. 
Hepatic deletion of Xbp1 leads to marked hyperactivation of IRE1α as 
previously reported (134, 211), made evident by robust splicing of the mutant XBP1 
expression and induction of both IRE1α protein and its phosphorylation. Hence, 
IRE1α is activated in Xbp1-deficient liver, suggesting feedback regulation of IRE1α 
by its downstream target XBP1 in an ER stress independent manner. The 
hyperactivation of IRE1α is considered to be associated with protection against 
APAP-mediated liver injury. Hur and colleagues (134) reported that IRE1α 
hyperactivation in hepatocytes results in reduced JNK activation and protection from 
APAP through activation of regulated IRE1α-dependent decay (RIDD) and 
regulating the stability of CYP450 activity by RIDD (134). RIDD was shown to 
reduce ER localized mRNA in mouse cells (212). The RIDD process selectively 
targets and degrades mRNA encoding proteins, which include but are not limited to 
mRNA encoding CYP450 drug-metabolizing enzymes. From our data, reduction of 
Cyp2e1 mRNA and protein levels were also observed in Xbp1-deficient mice with 
APAP-induced hepatotoxicity, and correspondingly intracellular free radicals and 
oxidative stress were also decreased in Xbp1-deficient mice.  
Consistent with the known role of XBP1 in the transcriptional regulation of 
hepatic lipogenesis (211), Xbp1∆hepa mice showed reduced hepatic lipid and 
triglyceride accumulation. RIDD also play important roles in hepatic lipid 
metabolism. IRE1 hyperactivation as a feedback of Xbp1 deficiency induced the 
degradation of mRNAs of a cohort of lipid metabolism genes, such as Dgat2, Acacb, 
Pcsk9, Angptl3 and Ces1, which regulate triglyceride and cholesterol metabolism at 
multiple levels. Suppression of RIDD by IRE1 siRNA markedly restored plasma 
triglyceride and cholesterol levels in Xbp1-deficient mice, along with the induction 
of lipid metabolism genes (213). Moreover, associated with IRE1α hyperactivation, 
CHOP and BiP/GRP78, and JNK1/2 were dramatically reduced in Xbp1-deficient 




crucial role in APAP-induced liver injury. However, JNK was not strongly activated 
in Xbp1-deficient mice, compared to Xbp1f/f mice, which might imply the possible 
mechanism of the observed protection from APAP liver toxicity. In addition, 
hepatocyte polarity and junctions-measured as ZO-1, and immune infiltration, 
inflammation and inflammasome activation were also ameliorated in Xbp1∆hepa 
animals after APAP injection. 
In recent years, accumulating evidences indicate that autophagy is activated in 
response to APAP overdose in specific liver zone areas, and protects against APAP-
induced liver injury (109, 214). Autophagy is a catabolic process that degrades and 
recycles damaged organelles and misfolded proteins through the lysosomal 
machinery (215, 216). Autophagy can eliminate damaged mitochondria and maintain 
mitochondrial homeostasis (217), which are the major source of intracellular ROS 
during APAP hepatotoxicity. Moreover, inhibition of autophagy exacerbated APAP-
induced liver injury while induction of autophagy have a protective effect against 
APAP hepatotoxicity (109). Besides, mitophagy critically mediates regulating cell 
death process through the removal of damage mitochondria (218). 
In our mice, TEM showed hepatocytes had normal ER ultrastructure in Xbp1∆hepa 
mice, but abundant autophagosomes formation and less mitochondrial damage under 
APAP toxicity. Additionally, Xbp1 deficiency significantly promoted the 
phosphorylation of AMPK, augmented the effect of APAP overdose on the induction 
of Atg5 and LC3-II levels and suppressed the levels of P62, indicating that APAP-
induced autophagosome formation in the liver was promoted by ablation of Xbp1 
gene. Autophagy starts from the formation of a double-membrane structure, the 
autophagosome, which enwrap cytoplasm and organelle. Autophagosomes then fuse 
with lysosomes to form autolysosomes thus degrading the enveloped contents (219). 
More than 30 Atg genes have been defined to participate in autophagy processes (220). 
The first step in vesicle nucleation is to activate Vps34 (Class III 
phosphatidylinositol 3-kinase), which associates with a complex formed by Beclin-1, 
UV radiation resistance and the kinase Vps15/p150 (221). Beclin-1 can also interact 




involves two ubiquitin-like binding steps. First, under the joint action of ATG7 (E1 
like) and ATG10 (E2 like), the proteins ATG12 and ATG5 are covalently bound 
together. Second, the conjugation of ATG8 with phosphatidylethanolamine (PE) in 
the autophagic vesicle membrane occurs after proteolytic cleavage by the cysteine 
protease ATG4. It is believed that the subsequent recruitment of ATG8 and other 
autophagy-related proteins will trigger vesicle expansion in a consistent manner (223). 
Transient conjugation of ATG8 to the membrane lipid PE is essential for the 
expansion of phagophore, because its mutations can cause defects in autophagosome 
formation (224). After vesicle expansion is completed, the autophagosome is ready 
to fuse with the lysosome, and ATG8 can be released from the membrane for 
recycling or degradation in the autolysate. The PE-conjugated and ATG4 cleavage 
form of LC3, called LC3-II, is commonly used as an autophagy marker (225). The 
regulatory process of autophagy involves the inhibition of mammalian target of 
rapamycin (mTOR) Ser/Thr kinase, which prevents autophagy through the 
phosphorylation of ATG13, and dissociates the protein from the complex formed by 
ATG1 (a protein kinase) and ATG17. Therefore, when mTOR becomes inhibited by, 
for example, rapamycin, autophagy is induced (226). AMPK is an upstream regulator 
targeting on the activity of the Unc-51 like autophagy activating kinase 1 (ULK1) 
complex. When cells suffer from stress, AMPK is activated and phosphorylates 
ULK1 and promotes autophagy (227, 228).  
The relationship between ER stress and autophagy is complex. Elucidation of 
the precise mechanism regulating autophagy is warranted to identify a therapeutic 
target for this prevalent and serious liver disease. Unfolded or misfolded proteins can 
be also reversed back to the cytoplasm and trigger ER-associated protein degradation 
(ERAD) which mainly consists of two mechanisms: ubiquitinproteasome-dependent 
ERAD and autophagy-lysosome dependent ERAD (229). Although it is recognized 
that ERAD is the main cellular mechanism for removing unfolded proteins during ER 
stress, many studies have shown that ER stress can effectively activate autophagy. 
For example, it has been reported that the release of Ca2+ from ER stimulates the 




suggested that the release of Ca2+ from the ER induced the activation of protein kinase 
C (PKC) and autophagy through an mTOR-independent mechanism (231). The 
PERK/elF2α signaling pathway has been proved to induce ATG12 expression and 
mediate autophagy through ATF4-driven transcriptional regulation of ATG genes 
(232, 233). In addition, previous studies have indicated that IRE1α forms a complex 
with TRAF2 and ASK1, which causes activation downstream of stress kinases JNK 
(194). JNK mediates phosphorylation of Bcl-2 and causes the release of Beclin-1, 
thereby promoting autophagy (221). 
Recently, accumulating evidence has revealed the bidirectional linkage between 
autophagy and ER stress (183, 234), and ER stress can modulate autophagy via the 
AMPK activation and AKT/mTOR inhibition (183, 234). AMPK can be activated 
under many conditions, such as hypoxia, DNA damage, glucose deprivation and free 
radical generation (235). Activated AMPK induces autophagy by direct 
phosphorylaiton of ULK1 at multiple sites, in turn initiating autophagosome 
formation (236). ULK1 is the most upstream signaling component of the core 
autophagy machinery (237). Our study showed the upregulation of pAMPK 
expression in Xbp1-deficient mice against APAP, which is parallel to IRE1α 
activation. These data give a possibility of regulatory cross talk between IRE1α-
XBP1 arm and AMPK signaling pathways. Gordon P Meares et al have proved that 
AMPK phosphorylation in response to nitric oxide is attenuated in cells depleted of 
IRE1α by siRNA knockdown, confirming that IRE1α participates in AMPK 
activation (238). Besides, activated AMPK then phosphorylates Raptor and 
influences mTOR signaling. mTOR is a key kinase regulating the synthesis and 
metabolism of protein and lipid, which can phosphorylate ULK1 at its inhibitory site 
(S757) and inhibit autophagy (239). The AKT/mTOR pathway has been recognized 
as a significant regulator of autophagy (240). Inhibition of the AKT/mTOR pathway 
has been reported to promote autophagy and apoptosis to produce anticancer effect 
(241). Our study showed that the overexpression of pAKT reduced expression of 




pathway markedly contributed to autophagy and protection against APAP in Xbp1-
deficient mice. 
Additionally, now it is also supported that an autophagy-cargo receptor complex, 
including ubiquitin and P62, mediates the selective autophagic removal of protein 
aggregates and organells (242). The increase in necrosis due to APAP toxicity in p62 
knockdown hepatocytes indicates that p62-mediated selective autophagy plays a role 
in protecting against APAP-induced liver injury (243). In terms of mechanism, P62 
directly binds to polyubiquitin or monoubiquitin through its C-terminal ubiquitin-
associated domain (UBA). P62 also directly binds to LC3 through its LC3-interaction 
region (LIR), thereby acting as a cargo adaptor for ubiquitinated proteins and linking 
them with autophagy degradation (244). P62 can bind to APAP-adducts (APAP-AD) 
and promote the transition of APAP-AD to a detergent-insoluble "protein aggregate"-
like structure, which can only be removed by autophagy. Therefore, P62 can be used 
as a selective receptor for APAP-AD for its selective autophagy removal. P62 also 
serves as a marker of autophagic flux through its involvement in recognizing cargo 
for autophagosomes. High cytoplasmic P62 expression accompanied with either a 
low or high LC3II expression indicates the impairment of autophagy under basal or 





Figure 23. Schematic diagram of the protective effects observed in Xbp1∆hepa mice. APAP 
hepatotoxicity induces ER stress and mitochondrial dysfunction. The ablation of Xbp1 in 
hepatocytes upregulates the expression of pIRE1α and promotes the activation of AMPK. 
Enhanced pAMPK expression is associated with an enhancement of autophagy (increased 
LC3-II formation and p62 degradation), which can degrade and recycle damaged organelles 
and misfolded proteins through the lysosomal machinery, thus protecting liver against APAP 
hepatotoxicity. Besides, activated IRE1α can limit translation of some mRNA through 
regulated IRE1α-regulated decay (RIDD). 
 
Furthermore, autophagy and inflammation are the two major innate immune 
pathways in the body that are mutually regulated by each other, which can control the 
invasion of pathogens. In 2008, Saitoh et al. reported for the first time that autophagy 
can regulate the activation of inflammasomes (245). Use of the inhibitors of 
autophagy or silencing Beclin, Atg7 or Atg5 can lead to the activation of 
inflammasomes (246), further confirming the regulatory role of autophagy in the 
activation of inflammasomes. Although it is generally believed that autophagy can 
regulate the activation of inflammasomes, the mechanism is not yet confirmed. 
Studies have found that at least the accumulation of ROS, mitochondrial DNA and 




that autophagy can selectively remove damaged mitochondria, inhibit the activation 
of inflammasomes, and delay the inflammatory response. In contrast, knockout of 
autophagy-related genes Lc3 and beclin1 can upregulate NLRP3 levels and increase 
inflammation (247). This also provides a possible explanation for the protective 
effects against APAP in Xbp1∆hepa animals.  
In summary, the present thesis provides a novel scheme in APAP-induced liver 
injury. APAP overdose could induce oxidative stress, ER stress and infiltration of 
inflammatory factors both in vivo and in vitro, thereby leading to cell death and liver 
parenchyma necrosis. However, ablation of Xbp1 in hepatocytes would protect 
against APAP hepatotoxicity, likely due to the activation of autophagy through the 
AMPK activation and AKT inhibition. Meanwhile, our team now are also checking 
the expression of Xbp1 in human liver suffering APAP damage, and tries to provide 




























1) APAP of 10 mM in HepaRG cells induces apparent hepatocyte death, loss 
of TJs and lipid accumulation. 
2) A sublethal dose of APAP (≥300 mg/kg) suffices to induce liver damage, 
hepatocyte necrosis, loss of TJs, oxidative stress, immune infiltration and 
inflammation and lipid accumulation in WT mice. 
3) Activation of the IRE1α-XBP1 arm and JNK1/2 is feature both in human 
and murine APAP-mediated hepatotoxicity, demonstrating the functionality 
of IRE1-XBP1 arm to the APAP-induced injury.  
4) Loss of Xbp1 in hepatocytes have a protective effect against APAP-induced 
liver injury, evidenced by decreased hepatocyte death and maintenance of 
TJs. 
5) Ablation of Xbp1 in hepatocytes decreases activation of UPR and JNK1/2 in 
response to a sublethal dose of APAP 
6) Ablation of Xbp1 in hepatocytes also reduces oxidative stress and lipid 
accumulation, ameliorates the infiltration of immune cells and inhibits 
activation of inflammasome. 
7) The protective effect in Xbp1∆hepa mice is likely due to the activation of 
autophagy via AMPK activation and AKT inhibition, which provides the 
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